# EAST Search History

| Ref # | Hits | Search Query | DBs | Default Operator | Plurals | Time Stamp |
|---|---|---|---|---|---|---|
| L1 | 17 | "6248755" | US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT; IBM_TDB | OR | ON | 2008/01/23 15:20 |
| L2 | 747 | 514/304.ccls. | US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT; IBM_TDB | OR | ON | 2008/01/23 16:10 |
| L3 | 37 | l2 and chemokine | US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT; IBM_TDB | OR | ON | 2008/01/23 16:10 |
| L4 | 11 | L2 and CCR | US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT; IBM_TDB | OR | ON | 2008/01/23 16:10 |

Print selected from 10528304.trn

**PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT**

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):0

=>
Uploading C:\Program Files\Stnexp\Queries\10528304\columbo.str



chain nodes :
12 22
ring nodes :
1 2 3 4 5 6 7 8 9 10 11 15 16 17 18 19 20
ring/chain nodes :
13 14
chain bonds :
6-11 12-14 12-13 13-22 17-22
ring bonds :
1-2 1-6 2-3 3-4 4-5 5-6 7-8 7-11 8-9 9-10 10-11 15-16 15-20 16-17
17-18
18-19 19-20
exact/norm bonds :
1-2 1-6 2-3 3-4 4-5 5-6 6-11 12-14 12-13 13-22
exact bonds :
7-8 7-11 8-9 9-10 10-11 17-22
normalized bonds :
15-16 15-20 16-17 17-18 18-19 19-20
isolated ring systems :
containing 1 : 7 :

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom
11:Atom 12:CLASS 13:CLASS 14:CLASS 15:Atom 16:Atom 17:Atom 18:Atom 19:Atom
20:Atom 22:CLASS

L5 STRUCTURE UPLOADED

=> d l5
L5 HAS NO ANSWERS
L5 STR



Print selected from 10528304.trn



Structure attributes must be viewed using STN Express query preparation.

=> s l5
SAMPLE SEARCH INITIATED 13:50:47 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 1014 TO ITERATE

100.0% PROCESSED 1014 ITERATIONS 29 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**
PROJECTED ITERATIONS: 18370 TO 22190
PROJECTED ANSWERS: 257 TO 903

L6 29 SEA SSS SAM L5

=> d scan

L6 29 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN Benzeneacetamide, α-[[[(4-chlorophenyl)amino]carbonyl]amino]-N-(1-cyclopentyl-4-piperidinyl)-, (αR)-
MF C25 H31 Cl N4 O2

Absolute stereochemistry.





Print selected from 10528304.trn

**PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT**

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L6 29 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN Cyclopentanecarboxamide, 1-[2-[(ethylamino)carbonyl]cyclopropyl]-3-[4-(4-fluorophenyl)-1-piperidinyl]-N-[[3-fluoro-5-(trifluoromethyl)phenyl]methyl]-
MF C31 H36 F5 N3 O2
CI COM



**PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT**

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L6 29 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN Cyclopentanecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-1-phenyl-3-(4-phenyl-1-piperidinyl)-, (1R,3S)-rel-
MF C32 H32 F6 N2 O

Relative stereochemistry.



**PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT**

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1



Print selected from 10528304.trn

L6 29 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN 1,1-Cyclopentanedicarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-3-[4-(4-fluorophenyl)-1-piperidinyl]-N'-methyl-
MF C28 H30 F7 N3 O2



**PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT**

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L6 29 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN Cyclopentanecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-3-[4-(4-fluorophenyl)-1-piperidinyl]-1-(1H-1,2,4-triazol-3-yl)-, (1R,3S)-rel-(9Cl)
MF C28 H26 F7 N5 O

Relative stereochemistry.



**PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT**

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L6 29 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN Cyclopentanecarboxamide, N-[[3-fluoro-5-(trifluoromethyl)phenyl]methyl]-1-[2-methylpropyl]-3-(4-phenyl-1-piperidinyl)-, (1S,3R)-
MF C29 H36 F4 N2 O

Absolute stereochemistry.



Print selected from 10528304.trn

**PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT**

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L6 29 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN Cyclopentanecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-1-(2-methylpropyl)-3-(1-piperidinyl)-
MF C24 H32 F6 N2 O



**PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT**

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L6 29 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN Cyclopentanecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-3-[4-(2,3-dihydro-2-oxo-1H-imidazol-1-yl)-1-piperidinyl]-1-[(1-methylethyl)-, (1R,3S)-rel-
MF C26 H32 F6 N4 O2

Relative stereochemistry.





Print selected from 10528304.trn



**PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT**

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):0

=> d his

(FILE 'HOME' ENTERED AT 13:45:02 ON 23 JAN 2008)

FILE 'REGISTRY' ENTERED AT 13:45:25 ON 23 JAN 2008
L1 STRUCTURE UPLOADED
L2 6 S L1
L3 STRUCTURE UPLOADED
L4 20 S L3
L5 STRUCTURE UPLOADED
L6 29 S L5

=> s l5 full
FULL SEARCH INITIATED 13:51:36 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 20032 TO ITERATE

100.0% PROCESSED 20032 ITERATIONS 412 ANSWERS
SEARCH TIME: 00.00.01

L7 412 SEA SSS FUL L5

=> file caplus
FILE 'CAPLUS' ENTERED AT 13:51:41 ON 23 JAN 2008
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

FILE COVERS 1907 - 23 Jan 2008 VOL 148 ISS 4
FILE LAST UPDATED: 22 Jan 2008 (20080122/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply.
They are available for your review at:

http://www.cas.org/infopolicy.html

=> s l7
L8 23 L7

=> d cbib abs hitstr 1-23

L8 ANSWER 1 OF 23 CAPLUS COPYRIGHT 2008 ACS on STN
2007:1237453 Document No. 147:502244 Preparation of 4-aminopiperidines and their use for treating sleep disorders. Van Kammen, Daniel; Weiner, David M.; Brann, Mark R.; Davis, Robert E. (Acadia Pharmaceuticals, Inc., USA). PCT Int. Appl. WO 2007124136 A1 20071101, 262pp. DESIGNATED STATES: W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG; RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, CY, DE, DK, ES, FI, FR, GA, GB, GR, IE, IS, IT, LU, MC, ML, MR, MT, NE, NL, PT, SE, SM, TD, TG, TR. (English). CODEN: PIXXD2. APPLICATION: WO 2007-US9804 20070419. PRIORITY: US 2006-793741P 20060419.

GI



I

AB The invention is related to the preparation of 4-aminopiperidine inverse agonists and antagonists of serotonin receptors, e.g., N-(4-fluorobenzyl)-N-(1-methylpiperidin-4-yl)-N'-[(4-(2-methylpropyloxy)phenyl] methyl]carbamide (I), for use in the treatment of sleep disorders such as insomnia, and specifically sleep maintenance insomnia. Thus, O-alkylation of 4-hydroxybenzaldehyde with iso-Bu bromide, oximation with NH2OH, hydrogenation of the oxime over Pd/C, treatment of the amine with phosgene, and reaction of N-[(4-fluorophenyl)methyl]-1-methylpiperidin-4-amine (prepared from N-methylpiperidin-4-one and 4-fluorobenzylamine) with the isocyanate intermediate (not isolated) gave aminopiperidine I. I exhibited high potency (pIC50 = 9.1) and high efficiency (96%) at 5HT2A receptors. Aminopiperidine I increased slow wave sleep, decreased the number of awakenings after sleep onset, decreased the time awake after sleep onset, did not alter latency to sleep onset and did not impair daytime





functioning.

IT 359879-94-0P, 2-(4-Chlorophenyl)-N-(4-methylbenzyl)-N-(1-cyclopentylpiperidin-4-yl)acetamide
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(drug candidate; preparation of 4-aminopiperidines and their use for treating sleep disorders)

RN 359879-94-0 CAPLUS
CN Benzeneacetamide, 4-chloro-N-(1-cyclopentyl-4-piperidinyl)-N-[(4-methylphenyl)methyl]- (CA INDEX NAME)



IT 359878-35-6P, 2-(4-Methoxyphenyl)-N-(4-chlorobenzyl)-N-(1-cyclopentylpiperidin-4-yl)acetamide hydrochloride 359878-96-9P, 2-(4-Methoxyphenyl)-N-(4-methylbenzyl)-N-(1-cyclopentylpiperidin-4-yl)acetamide 359881-73-5P, 2-(4-Chlorophenyl)-N-(4-methylbenzyl)-N-(1-cyclopentylpiperidin-4-yl)acetamide hydrochloride
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(drug candidate; preparation of 4-aminopiperidines and their use for treating sleep disorders)

RN 359878-35-6 CAPLUS
CN Benzeneacetamide, N-[(4-chlorophenyl)methyl]-N-(1-cyclopentyl-4-piperidinyl)-4-methoxy-, hydrochloride (1:1) (CA INDEX NAME)



● HCl





RN 359878-96-9 CAPLUS
CN Benzeneacetamide, N-(1-cyclopentyl-4-piperidinyl)-4-methoxy-N-[(4-methylphenyl)methyl]- (CA INDEX NAME)



RN 359881-73-5 CAPLUS
CN Benzeneacetamide, 4-chloro-N-(1-cyclopentyl-4-piperidinyl)-N-[(4-methylphenyl)methyl]-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

L9 ANSWER 2 OF 23 CAPLUS COPYRIGHT 2008 ACS on STN
2007:1176632 Document No. 147:486430 Preparation of thiazolyldihydroindazoles as PI-3 kinase inhibitors. Maier, Udo; Grauert, Matthias; Hoffmann, Matthias; Hoenke, Christoph; Joergensen, Anne T.; Pautsch, Alexander; Brandl, Trixi; Breitfelder, Steffen; Scheuerer, Stefan; Erb, Klaus; Pieper, Michael; Praqst, Ingo (Boehringer Ingelheim International G.m.b.H., Germany; Boehringer Ingelheim Pharma G.m.b.H. & Co. K.-G.). PCT Int. Appl. WO 2007115930 A1 20071018, 188pp. DESIGNATED STATES: W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK,





SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG; RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, CY, DE, DK, ES, FI, FR, GA, GB, GR, IE, IS, IT, LU, MC, ML, MR, MT, NE, NL, PT, SE, SN, TD, TG, TR. (German). CODEN: PIXXD2. APPLICATION: WO 2007-EP52913 20070327. PRIORITY: EP 2006-112299 20060406.

GI



I



II

AB Title compds. I [R1 = H, alkyl, cycloalkyl, etc.; R2 = H, alkyl, cycloalkyl, etc.; R3 = H, alkyl, alkenyl, etc.; R4 = H, alkyl, cycloalkyl, etc.] and their pharmaceutically acceptable salts and formulations were prepared. For example, condensation of dimethylamine and acid II [X =OH] afforded pyrazole II [X = NMe2] in 32% yield. Compds. I are claimed useful as PI-3 kinase inhibitors.

IT 953050-50-5P 953051-18-8P 953051-19-9P
953051-20-2P 953051-21-3P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of thiazolyldihydroindazoles as PI-3 kinase inhibitors)

RN 953050-50-5 CAPLUS
CN Urea, N-[1-(1-cyclopentyl-4-piperidinyl)-4,5-dihydro-3-(3-pyridinyl)-1H-pyrazolo[4,3-g]benzothiazol-7-yl]-N'-[[3-(2-oxo-1-imidazolidinyl)phenyl]methyl]- (CA INDEX NAME)







RN 953051-18-8 CAPLUS
CN Benzamide, 3-[[[[[1-(1-cyclopentyl-4-piperidinyl)-4,5-dihydro-3-(3-pyridinyl)-1H-pyrazolo[4,3-g]benzothiazol-7-yl]amino]carbonyl]amino]methyl]- (CA INDEX NAME)



RN 953051-19-9 CAPLUS
CN Benzamide, 3-[[[[[1-(1-cyclopentyl-4-piperidinyl)-4,5-dihydro-3-(3-pyridinyl)-1H-pyrazolo[4,3-g]benzothiazol-7-yl]amino]carbonyl]amino]methyl]-N-methyl- (CA INDEX NAME)







RN 953051-20-2 CAPLUS
CN Acetamide, N-[3-[[[[[1-(1-cyclopentyl-4-piperidinyl)-4,5-dihydro-3-(3-pyridinyl)-1H-pyrazolo[4,3-g]benzothiazol-7-yl]amino]carbonyl]amino]methyl]phenyl]- (CA INDEX NAME)



RN 953051-21-3 CAPLUS
CN Urea, N-[1-(1-cyclopentyl-4-piperidinyl)-4,5-dihydro-3-(3-pyridinyl)-1H-pyrazolo[4,3-g]benzothiazol-7-yl]-N'-[(3-methoxyphenyl)methyl]- (CA INDEX NAME)



L9 ANSWER 3 OF 23 CAPLUS COPYRIGHT 2008 ACS on STN
2007:868265 Document No. 147:203992 Drug compositions containing piperidine compounds with tachykinin receptor antagonistic activities. Miyake, Tsutomu; Yamanaka, Takeshi; Terakawa, Yoshihiro; Asai, Hidetoshi (Tanabe Seiyaku Co., Ltd., Japan). Jpn. Kokai Tokkyo Koho JP 2007197429 A 20070803, 119pp. (Japanese). CODEN: JKXXAF. APPLICATION: JP 2006-349025 20061226. PRIORITY: JP 2005-376753 20051228.

GI



1

AB The invention provides a drug composition characterized by containing a piperidine
compound represented by a formula 1 [A, B = (un)substituted benzene ring; R1 = H, substituent for amino group; R2 = H, (un)substituted OH, (un)substituted amino, (un)substituted alkyl, (un)substituted carbonyl, halogen; Z = O, N(R3) (R3 = H, (un)substituted alkyl); R4a, R4b = H, (un)substituted alkyl, alkylene], or its pharmaceutically acceptable salt as an active component. The compound has tachykinin receptor antagonistic activity, and suitable for use for treatment and/or prevention of urination disorder, etc. For example, (3S,4S)-1-[(1-acetylpiperidin-4-yl)carbonyl]-4-[[N-[1-(R)-[3,5-bis(trifluoromethyl)phenyl]ethyl]-N-methylamino]carbonyl]-3-(4-fluoro-2-methylphenyl)piperidine was prepared, and examined for its NK1 receptor antagonistic effect in vitro, and its effect on urinary frequency in guinea pigs.

IT 873460-64-1P 873460-65-2P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(drug compns. containing piperidine compds. with tachykinin receptor antagonistic activities)

RN 873460-64-1 CAPLUS
CN 4-Piperidinecarboxamide, N-[(1R)-1-[3,5-bis(trifluoromethyl)phenyl]ethyl]-1-cyclopentyl-3-(4-fluoro-2-methylphenyl)-N-methyl-, (3S,4S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 873460-65-2 CAPLUS
CN 4-Piperidinecarboxamide, N-[(1S)-1-[3,5-bis(trifluoromethyl)phenyl]ethyl]-





1-cyclopentyl-3-(4-fluoro-2-methylphenyl)-N-methyl-, (3S,4S)- (CA INDEX NAME)

Absolute stereochemistry.



L8 ANSWER 4 OF 23 CAPLUS COPYRIGHT 2008 ACS on STN
2007:460081 Document No. 147:86248 Discovery of 3-Piperidinyl-1-cyclopentanecarboxamide as a Novel Scaffold for Highly Potent CC Chemokine Receptor 2 Antagonists. Yang, Lihu; Butora, Gabor; Jiao, Richard X.; Pasternak, Alex; Zhou, Changyou; Parsons, William H.; Mills, Sander G.; Vicario, Pasquale P.; Ayala, Julia M.; Cascieri, Margaret A.; MacCoss, Malcolm (Merck Research Laboratories, Rahway, NJ, 07065, USA). Journal of Medicinal Chemistry, 50(11), 2609-2611 (English) 2007. CODEN: JMCMAR. ISSN: 0022-2623. OTHER SOURCES: CASREACT 147:86249. Publisher: American Chemical Society.

GI



I

AB Introduction of ring restrictions to a linear aminobutyramide CC chemokine receptor 2 (CCR2) antagonist lead (2) led to the discovery of a 1,3-disubstituted cyclopentane scaffold with enhanced hCCR2 receptor binding and antagonist activity. (1S,3R)-N-[3,5-Bis(trifluoromethyl)benzyl]-1-methyl-3-[(1R,3'R)-methyl-1'H-spiro[indene-1,4'-piperidin]-1'-yl]cyclopentanecarboxamide (16) (I) had IC50 of 1.3 nM (binding) and 0.45 nM (functional chemotaxis) against hCCR2. It also showed activity against the mouse CCR2 receptor with an IC50 of 130 nM. Compound 16 is selective against other chemokine receptors, including CCR5 (.apprx.500-fold).

IT 400765-60-8P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES





(Uses)
(Discovery of 3-Piperidinyl-1-cyclopentanecarboxamide as a Novel Scaffold for Highly Potent CC Chemokine Receptor 2 Antagonists)

RN 400765-60-8 CAPLUS
CN Cyclopentanecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-3-(4-phenyl-1-piperidinyl)- (CA INDEX NAME)



L8 ANSWER 5 OF 23 CAPLUS COPYRIGHT 2008 ACS on STN
2006:471760 Document No. 144:488537 Quinolinecarboxamides having activity at NK3 receptor and their preparations, pharmaceutical compositions and use for treatment of disease mediated by modulation of NK3 receptors. Smith, Paul William; Wyman, Paul Adrian (Smithkline Beecham Corporation, USA). PCT Int. Appl. WO 2006050992 A1 20060518, 51 pp. DESIGNATED STATES: W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW; RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, CY, DE, DK, ES, FI, FR, GA, GB, GR, IE, IS, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN, TD, TG, TR. (English). CODEN: PIXXD2. APPLICATION: WO 2005-EP12210 20051110. PRIORITY: GB 2004-25076 20041112.

GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB The invention relates to compds. of formula I, a pharmaceutically acceptable salt, solvate or prodrug thereof. Compds. of formula I wherein R1 is (un)substituted Ph or (un)substituted cyclohexyl; X is O or S; R2 is C1-6alkyl, C3-6cycloalkyl, or acetyl; a is 1, 2, or 3; b is 0 or 1; c is 0, 1 or 2; R3 is H or C1-6alkyl; R4 is H, C1-6alkyl, C1-6haloalkyl, C1-4alkoxyC1-6alkyl, C3-6cycloalkyl, or C3-6cycloalkylC1-6alkyl; R5 is H; R6 is (un)substituted Ph or (un)substituted thienyl; m is 0, 1 or 2; wherein when m is 1 or 2, Y is a halogen atom, and wherein when m is 2 the halogen atoms may be the same or different and their pharmaceutically acceptable salts, solvates, or prodrug thereof are claimed. Also disclosed are use of the compds. in treating diseases and conditions mediated by activation of the NK3 receptor, in particular in treating CNS disorders, compns. containing the derivs. and processes for their preparation Example compound 11 was prepared by amidation of 2-((S)-1-methylpyrrolidin-2-ylmethoxymethyl)-2-phenylquinoline-4-carboxylic acid hydrochloride with (S)-1-cyclopropyl-1-phenylmethylamine hydrochloride. All the invention compds. were evaluated for their NK3 binding affinity. From the assay, it was determined that all the example compds. exhibited pKi equal to or greater than 7.5 and the preferred compds. gave a pKi equal to or greater than





6.2. Example compound 11 gave a pKi of 9.2.

IT 887396-84-1P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(drug candidate; preparation of quinolinecarboxamides having activity at NK3 receptor and their use for treatment of disease mediated by modulation of NK3 receptors)

RN 887396-84-1 CAPLUS
CN 4-Quinolinecarboxamide, 3-[[(1-cyclopentyl-4-piperidinyl)oxy]methyl]-2-phenyl-N-[(1S)-1-phenylpropyl]- (CA INDEX NAME)

Absolute stereochemistry.



L8 ANSWER 6 OF 23 CAPLUS COPYRIGHT 2006 ACS on STN
2006:31721 Document No. 144:129859 Preparation of piperidine-4-carboxylic acid amides and esters as tachykinin receptor antagonists. Miyake, Tsutomu; Yamanaka, Takeshi; Asai, Hidetoshi; Terakawa, Yoshihiro (Tanabe Seiyaku Co., Ltd., Japan). PCT Int. Appl. WO 2006004195 A1 20060112, 152 pp. DESIGNATED STATES: W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW; RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, CY, DE, DK, ES, FI, FR, GA, GB, GR, IE, IS, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN, TD, TG, TR. (English). CODEN: PIXXD2. APPLICATION: WO 2005-JP12630 20050701. PRIORITY: JP 2004-196360 20040702.

GI







I



II

AB The present invention provides piperidine-4-carboxylic acid amides and esters (shown as I; ring A is an (un)substituted benzene ring, ring B is an (un)substituted benzene ring; R1 is H atom or a substituent for amino group, R2 is H atom, an (un)substituted hydroxyl group, an (un)substituted amino group, an (un)substituted alkyl group, a substituted carbonyl group or a halogen atom; Z is O atom or -N(R3)-; R3 is H atom or an (un)substituted alkyl group; R4a and R4b may be the same or different, and each is H atom or an (un)substituted alkyl group, or may be bonded to each other at the both ends to form an alkylene group; e.g. (3S,4S)-1-tert-butoxycarbonyl-4-[[N-[1-(R)-[3,5-bis(trifluoromethyl)phenyl]ethyl]-N-methylamino]carbonyl]-3-(4-fluoro-2-methylphenyl)piperidine (shown as II) and (3S,4R)-1-tert-butoxycarbonyl-4-[[N-[1-(R)-[3,5-bis(trifluoromethyl)phenyl]ethyl]-N-methylamino]carbonyl]-3-(4-fluoro-2-methylphenyl)piperidine) or pharmaceutically acceptable salts thereof, which have an excellent tachykinin receptor antagonistic action (no data). Methods of preparation are claimed and prepns. and/or characterization data for >300 examples of I are included. For example, II and its diastereomer were prepared from 1-tert-butoxycarbonyl-4-carboxy-3-(4-fluoro-2-methylphenyl)piperidine and N-[(R)-1-[3,5-bis[trifluoromethyl]phenyl]ethyl]-N-methylamine using 1-[3-(dimethylamino)propyl]-3-ethylcarbodiimide hydrochloride and 1-hydroxybenzotriazole in DMF.

IT 873460-64-1P 873460-65-2P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(drug candidate; preparation of piperidine-4-carboxylic acid amides and esters as tachykinin receptor antagonists)

RN 873460-64-1 CAPLUS
CN 4-Piperidinecarboxamide, N-[(1R)-1-[3,5-bis(trifluoromethyl)phenyl]ethyl]-





1-cyclopentyl-3-(4-fluoro-2-methylphenyl)-N-methyl-, (3S,4S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 873460-65-2 CAPLUS
CN 4-Piperidinecarboxamide, N-[(1S)-1-[3,5-bis(trifluoromethyl)phenyl]ethyl]-1-cyclopentyl-3-(4-fluoro-2-methylphenyl)-N-methyl-, (3S,4S)- (CA INDEX NAME)

Absolute stereochemistry.



L8 ANSWER 7 OF 23 CAPLUS COPYRIGHT 2006 ACS on STN
2004:1124569 Document No. 142:69197 CCR-2 antagonists for treatment of neuropathic pain. Abbadie, Catherine; Lindia, Jill Ann; Wang, Hao (Merck & Co., Inc., USA). PCT Int. Appl. WO 2004110376 A2 20041223, 304 pp. DESIGNATED STATES: W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW; RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, CY, DE, DK, ES, FI, FR, GA, GB, GR, IE, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN, TD, TG, TR. (English). CODEN: PIXXD2. APPLICATION: WO 2004-US17499 20040602. PRIORITY: US 2003-476391P 20030606; US 2003-531537P 20031222.

AB The invention is directed to methods of treating neuropathic pain and other neuropathic diseases and conditions with CCR-2 antagonists and pharmaceutical composition containing CCR-2 antagonists.

IT 690262-08-9P 690262-09-0P 690262-10-3P
690262-11-4P 690262-12-5P 690262-13-6P
690262-14-7P 690262-15-8P 690262-16-9P
690262-17-0P 690262-18-1P 690262-19-2P
690262-20-5P 690262-21-6P 690262-22-7P
690262-23-8P 690262-24-9P 690262-25-0P
690262-26-1P 690262-27-2P 690262-28-3P
690262-29-4P 690262-30-7P 690262-31-8P
690262-32-9P 690262-33-0P 690262-34-1P
690262-35-2P 690262-36-3P 690262-37-4P
690262-38-5P 690262-39-6P 690262-40-9P
690262-41-0P 690262-42-1P 690262-43-2P
690262-44-3P 690262-45-4P 690262-46-5P
690262-47-6P 690262-48-7P 690262-49-8P
690262-50-1P 690262-51-2P 690262-52-3P
690262-53-4P 690262-54-5P 690262-55-6P
690262-56-7P 690262-57-8P 690262-58-9P
690262-59-0P 690262-60-3P 690262-61-4P
690262-62-5P 690262-63-6P 690262-64-7P
690262-65-8P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(CCR2 antagonists for treatment of neuropathic pain)

RN 690262-08-9 CAPLUS
CN Cyclopentanecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-1-(1-methylethyl)-3-[4-(2H-1,2,3-triazol-2-yl)-1-piperidinyl]-, (1R,3S)-rel- (CA INDEX NAME)

Relative stereochemistry.



RN 690262-09-0 CAPLUS
CN Cyclopentanecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-1-(1-methylethyl)-3-[4-(1H-1,2,3-triazol-1-yl)-1-piperidinyl]-, (1R,3S)-rel- (CA INDEX NAME)

Relative stereochemistry.







RN 690262-15-8 CAPLUS
CN Cyclopentanecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-1-(1-methylethyl)-3-[4-(1H-pyrrol-1-yl)-1-piperidinyl]-, (1R,3S)-rel- (CA INDEX NAME)

Relative stereochemistry.



RN 690262-16-9 CAPLUS
CN Cyclopentanecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-1-(1-methylethyl)-3-[4-(1H-pyrazol-1-yl)-1-piperidinyl]-, (1R,3S)-rel- (CA INDEX NAME)

Relative stereochemistry.









RN 690262-10-3 CAPLUS
CN Cyclopentanecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-1-(1-methylethyl)-3-[4-(1H-1,2,4-triazol-1-yl)-1-piperidinyl]-, (1R,3S)-rel- (CA INDEX NAME)

Relative stereochemistry.



RN 690262-11-4 CAPLUS
CN Cyclopentanecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-1-(1-methylethyl)-3-[4-(2H-tetrazol-2-yl)-1-piperidinyl]-, (1R,3S)-rel- (CA INDEX NAME)

Relative stereochemistry.







RN 690262-17-0 CAPLUS
CN Cyclopentanecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-1-(1-methylethyl)-3-[4-(4H-1,2,4-triazol-4-yl)-1-piperidinyl]-, (1R,3S)-rel- (CA INDEX NAME)

Relative stereochemistry.



RN 690262-18-1 CAPLUS
CN Cyclopentanecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-1-(1-hydroxy-1-methylethyl)-3-[4-(1H-pyrazol-1-yl)-1-piperidinyl]-, (1R,3S)-rel- (CA INDEX NAME)

Relative stereochemistry.



RN 690262-19-2 CAPLUS
CN Cyclopentanecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-1-(1-hydroxy-1-methylethyl)-3-[4-(1H-imidazol-1-yl)-1-piperidinyl]-, (1R,3S)-rel- (CA INDEX NAME)

Relative stereochemistry.





RN 690262-12-5 CAPLUS
CN Cyclopentanecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-1-(1-methylethyl)-3-[4-(1H-tetrazol-1-yl)-1-piperidinyl]-, (1R,3S)-rel- (CA INDEX NAME)

Relative stereochemistry.



RN 690262-13-6 CAPLUS
CN Cyclopentanecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-1-(1-methylethyl)-3-[4-(5-methyl-2H-tetrazol-2-yl)-1-piperidinyl]-, (1R,3S)-rel- (CA INDEX NAME)

Relative stereochemistry.



RN 690262-14-7 CAPLUS
CN Cyclopentanecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-3-[4-(1H-imidazol-1-yl)-1-piperidinyl]-1-(1-methylethyl)-, (1R,3S)-rel- (CA INDEX NAME)

Relative stereochemistry.







RN 690262-20-5 CAPLUS
CN Cyclopentanecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-1-(1-hydroxy-1-methylethyl)-3-[4-(2H-1,2,3-triazol-2-yl)-1-piperidinyl]-, (1R,3S)-rel- (CA INDEX NAME)

Relative stereochemistry.



RN 690262-21-6 CAPLUS
CN Cyclopentanecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-1-(1-hydroxy-1-methylethyl)-3-[4-(1H-1,2,3-triazol-1-yl)-1-piperidinyl]-, (1R,3S)-rel- (CA INDEX NAME)

Relative stereochemistry.



RN 690262-22-7 CAPLUS
CN Cyclopentanecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-1-(1-hydroxy-1-methylethyl)-3-[4-(1H-1,2,4-triazol-1-yl)-1-piperidinyl]-, (1R,3S)-rel- (CA INDEX NAME)

Relative stereochemistry.



RN 690262-23-8 CAPLUS
CN Cyclopentanecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-1-(1-hydroxy-1-methylethyl)-3-[4-(1H-tetrazol-1-yl)-1-piperidinyl]-, (1R,3S)-rel- (CA INDEX NAME)

Relative stereochemistry.





RN 690262-28-3 CAPLUS
CN Cyclopentanecarboxamide, N-[[3-fluoro-5-(trifluoromethyl)phenyl]methyl]-1-(1-methylethyl)-3-[4-(1H-1,2,3-triazol-1-yl)-1-piperidinyl]-, (1R,3S)-rel- (CA INDEX NAME)

Relative stereochemistry.



RN 690262-29-4 CAPLUS
CN Cyclopentanecarboxamide, N-[[3-fluoro-5-(trifluoromethyl)phenyl]methyl]-1-(1-methylethyl)-3-[4-(1H-1,2,4-triazol-1-yl)-1-piperidinyl]-, (1R,3S)-rel- (CA INDEX NAME)

Relative stereochemistry.



RN 690262-30-7 CAPLUS
CN Cyclopentanecarboxamide, N-[[3-fluoro-5-(trifluoromethyl)phenyl]methyl]-1-(1-methylethyl)-3-[4-(1H-tetrazol-1-yl)-1-piperidinyl]-, (1R,3S)-rel- (CA INDEX NAME)

Relative stereochemistry.







RN 690262-24-9 CAPLUS
CN Cyclopentanecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-1-(1-hydroxy-1-methylethyl)-3-[4-(2H-tetrazol-2-yl)-1-piperidinyl]-, (1R,3S)-rel- (CA INDEX NAME)

Relative stereochemistry.



RN 690262-25-0 CAPLUS
CN Cyclopentanecarboxamide, N-[[3-fluoro-5-(trifluoromethyl)phenyl]methyl]-1-(1-methylethyl)-3-[4-(1H-pyrazol-1-yl)-1-piperidinyl]-, (1R,3S)-rel- (CA INDEX NAME)

Relative stereochemistry.







RN 690262-31-8 CAPLUS
CN Cyclopentanecarboxamide, N-[[3-fluoro-5-(trifluoromethyl)phenyl]methyl]-1-(1-methylethyl)-3-[4-(2H-tetrazol-2-yl)-1-piperidinyl]-, (1R,3S)-rel- (CA INDEX NAME)

Relative stereochemistry.



RN 690262-32-9 CAPLUS
CN Cyclopentanecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-3-[4-(1H-indazol-1-yl)-1-piperidinyl]-1-(1-methylethyl)-, (1R,3S)-rel- (CA INDEX NAME)

Relative stereochemistry.









RN 690262-26-1 CAPLUS
CN Cyclopentanecarboxamide, N-[[3-fluoro-5-(trifluoromethyl)phenyl]methyl]-3-[4-(1H-imidazol-1-yl)-1-piperidinyl]-1-(1-methylethyl)-, (1R,3S)-rel- (CA INDEX NAME)

Relative stereochemistry.



RN 690262-27-2 CAPLUS
CN Cyclopentanecarboxamide, N-[[3-fluoro-5-(trifluoromethyl)phenyl]methyl]-1-(1-methylethyl)-3-[4-(2H-1,2,3-triazol-2-yl)-1-piperidinyl]-, (1R,3S)-rel- (CA INDEX NAME)

Relative stereochemistry.







RN 690262-33-0 CAPLUS
CN Cyclopentanecarboxamide, N-[[3-fluoro-5-(trifluoromethyl)phenyl]methyl]-1-(1-hydroxy-1-methylethyl)-3-[4-(1H-pyrazol-1-yl)-1-piperidinyl]-, (1R,3S)-rel- (CA INDEX NAME)

Relative stereochemistry.



RN 690262-34-1 CAPLUS
CN Cyclopentanecarboxamide, N-[[3-fluoro-5-(trifluoromethyl)phenyl]methyl]-1-(1-hydroxy-1-methylethyl)-3-[4-(1H-imidazol-1-yl)-1-piperidinyl]-, (1R,3S)-rel- (CA INDEX NAME)

Relative stereochemistry.



RN 690262-35-2 CAPLUS
CN Cyclopentanecarboxamide, N-[[3-fluoro-5-(trifluoromethyl)phenyl]methyl]-1-(1-hydroxy-1-methylethyl)-3-[4-(2H-1,2,3-triazol-2-yl)-1-piperidinyl]-, (1R,3S)-rel- (CA INDEX NAME)

Relative stereochemistry.





RN 690262-36-3 CAPLUS
CN Cyclopentanecarboxamide, N-[[3-fluoro-5-(trifluoromethyl)phenyl]methyl]-1-(1-hydroxy-1-methylethyl)-3-[4-(1H-1,2,3-triazol-1-yl)-1-piperidinyl]-, (1R,3S)-rel- (CA INDEX NAME)

Relative stereochemistry.





RN 690262-37-4 CAPLUS
CN Cyclopentanecarboxamide, N-[[3-fluoro-5-(trifluoromethyl)phenyl]methyl]-1-(1-hydroxy-1-methylethyl)-3-[4-(1H-1,2,4-triazol-1-yl)-1-piperidinyl]-, (1R,3S)-rel- (CA INDEX NAME)

Relative stereochemistry.







RN 690262-42-1 CAPLUS
CN Cyclopentanecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-3-[4-(1H-imidazol-2-yl)-1-piperidinyl]-1-(1-methylethyl)-, (1R,3S)-rel- (CA INDEX NAME)

Relative stereochemistry.



RN 690262-43-2 CAPLUS
CN Cyclopentanecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-1-(1-methylethyl)-3-[4-(2-thiazolyl)-1-piperidinyl]-, (1R,3S)-rel- (CA INDEX NAME)

Relative stereochemistry.











RN 690262-38-5 CAPLUS
CN Cyclopentanecarboxamide, N-[[3-fluoro-5-(trifluoromethyl)phenyl]methyl]-1-(1-hydroxy-1-methylethyl)-3-[4-(1H-tetrazol-1-yl)-1-piperidinyl]-, (1R,3S)-rel- (CA INDEX NAME)

Relative stereochemistry.





RN 690262-39-6 CAPLUS
CN Cyclopentanecarboxamide, N-[[3-fluoro-5-(trifluoromethyl)phenyl]methyl]-1-(1-hydroxy-1-methylethyl)-3-[4-(2H-tetrazol-2-yl)-1-piperidinyl]-, (1R,3S)-rel- (CA INDEX NAME)

Relative stereochemistry.





RN 690262-44-3 CAPLUS
CN Cyclopentanecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-1-(1-methylethyl)-3-[4-(1H-pyrazol-3-yl)-1-piperidinyl]-, (1R,3S)-rel- (CA INDEX NAME)

Relative stereochemistry.



RN 690262-45-4 CAPLUS
CN Cyclopentanecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-1-(1-hydroxy-1-methylethyl)-3-[4-(1-methyl-1H-tetrazol-5-yl)-1-piperidinyl]-, (1R,3S)-rel- (CA INDEX NAME)

Relative stereochemistry.





RN 690262-46-5 CAPLUS
CN Cyclopentanecarboxamide, N-[[3-fluoro-5-(trifluoromethyl)phenyl]methyl]-1-(1-methylethyl)-3-[4-(1H-pyrazol-3-yl)-1-piperidinyl]-, (1R,3S)-rel- (CA INDEX NAME)

Relative stereochemistry.









RN 690262-40-9 CAPLUS
CN Cyclopentanecarboxamide, 3-[4-(1H-benzimidazol-1-yl)-1-piperidinyl]-N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-1-(1-methylethyl)-, (1R,3S)-rel- (CA INDEX NAME)

Relative stereochemistry.



RN 690262-41-0 CAPLUS
CN Cyclopentanecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-3-[4-(2,3-dihydro-2-oxo-1H-imidazol-1-yl)-1-piperidinyl]-1-(1-methylethyl)-, (1R,3S)-rel- (CA INDEX NAME)

Relative stereochemistry.







RN 690262-47-6 CAPLUS
CN Cyclopentanecarboxamide, N-[[3-fluoro-5-(trifluoromethyl)phenyl]methyl]-1-(1-methylethyl)-3-[4-(1-methyl-1H-tetrazol-5-yl)-1-piperidinyl]-, (1R,3S)-rel- (CA INDEX NAME)

Relative stereochemistry.



RN 690262-48-7 CAPLUS
CN Cyclopentanecarboxamide, N-[[3-fluoro-5-(trifluoromethyl)phenyl]methyl]-1-(1-hydroxy-1-methylethyl)-3-[4-(1H-pyrazol-2-yl)-1-piperidinyl]-, (1R,3S)-rel- (CA INDEX NAME)

Relative stereochemistry.



RN 690262-49-8 CAPLUS
CN Cyclopentanecarboxamide, N-[[3-fluoro-5-(trifluoromethyl)phenyl]methyl]-1-(1-hydroxy-1-methylethyl)-3-[4-(1-methyl-1H-tetrazol-5-yl)-1-piperidinyl]-, (1R,3S)-rel- (CA INDEX NAME)

Relative stereochemistry.



RN 690262-50-1 CAPLUS
CN Cyclopentanecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-1-(1-methylethyl)-3-(4-pyrazinyl-1-piperidinyl)-, (1R,3S)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.







RN 690262-56-7 CAPLUS
CN Carbamic acid, [4-[1-[[(1R,3S)-3-[[[[3,5-bis(trifluoromethyl)phenyl]methyl]amino]carbonyl]-3-(1-methylethyl)cyclopentyl]-4-piperidinyl]-2-thiazolyl]-, methyl ester, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 690262-57-8 CAPLUS
CN Cyclopentanecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-1-(1-methylethyl)-3-[4-[2-[(methylsulfonyl)amino]-4-thiazolyl]-1-piperidinyl]-, (1R,3S)-rel- (CA INDEX NAME)

Relative stereochemistry.









RN 690262-51-2 CAPLUS
CN Cyclopentanecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-1-(1-methylethyl)-3-[4-(2-pyrimidinyl)-1-piperidinyl]-, (1R,3S)-rel- (CA INDEX NAME)

Relative stereochemistry.



RN 690262-52-3 CAPLUS
CN Cyclopentanecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-3-[4-(6-chloro-3-pyridazinyl)-1-piperidinyl]-1-(1-methylethyl)-, (1R,3S)-rel- (CA INDEX NAME)

Relative stereochemistry.







RN 690262-58-9 CAPLUS
CN Cyclopentanecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-3-[4-(2,5-dihydro-5-oxo-1,2,4-thiadiazol-3-yl)-1-piperidinyl]-1-(1-methylethyl)-, (1R,3S)-rel- (CA INDEX NAME)

Relative stereochemistry.



RN 690262-59-0 CAPLUS
CN Cyclopentanecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-1-(1-methylethyl)-3-[4-(4H-pyrazol-4-yl)-1-piperidinyl]-, (1R,3S)-rel- (CA INDEX NAME)

Relative stereochemistry.



RN 690262-60-3 CAPLUS
CN Cyclopentanecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-1-(1-methylethyl)-3-[4-(3-pyridinyl)-1-piperidinyl]-, (1R,3S)-rel- (CA INDEX NAME)

Relative stereochemistry.





RN 690262-53-4 CAPLUS
CN Cyclopentanecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-1-(1-methylethyl)-3-[4-(3-pyridazinyl)-1-piperidinyl]-, (1R,3S)-rel- (CA INDEX NAME)

Relative stereochemistry.



RN 690262-54-5 CAPLUS
CN Cyclopentanecarboxamide, 3-[4-(2-amino-4-thiazolyl)-1-piperidinyl]-N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-1-(1-methylethyl)-, (1R,3S)-rel- (CA INDEX NAME)

Relative stereochemistry.



RN 690262-55-6 CAPLUS
CN Cyclopentanecarboxamide, 3-[4-[2-(acetylamino)-4-thiazolyl]-1-piperidinyl]-N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-1-(1-methylethyl)-, (1R,3S)-rel- (CA INDEX NAME)

Relative stereochemistry.







RN 690262-61-4 CAPLUS
CN Cyclopentanecarboxamide, 3-[4-[2-(acetylamino)-5-thiazolyl]-1-piperidinyl]-N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-1-(1-methylethyl)-, (1R,3S)-rel- (CA INDEX NAME)

Relative stereochemistry.



RN 690262-62-5 CAPLUS
CN Carbamic acid, [5-[1-[(1R,3S)-3-[[[[3,5-bis(trifluoromethyl)phenyl]methyl]amino]carbonyl]-3-(1-methylethyl)cyclopentyl]-4-piperidinyl]-2-thiazolyl]-, phenylmethyl ester, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 690262-63-6 CAPLUS
CN Cyclopentanecarboxamide, 3-[4-(2-amino-5-thiazolyl)-1-piperidinyl]-N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-1-(1-methylethyl)-, (1R,3S)-rel- (CA INDEX NAME)

Relative stereochemistry.



RN 690262-64-7 CAPLUS
CN Cyclopentanecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-1-(1-methylethyl)-3-[4-(4-pyridazinyl)-1-piperidinyl]-, (1R,3S)-rel- (CA INDEX NAME)

Relative stereochemistry.





ZA, ZM, ZW; RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, CY, DE, DK, ES, FI, FR, GA, GB, GR, IE, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN, TD, TG, TR. (English). CODEN: PIXXD2. APPLICATION: WO 2003-US34002 20031024. PRIORITY: US 2002-422447P 20021030.

GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB The invention relates to heteroarylpiperidine derivs. of formula I [wherein: R1 is H, C0-6alkyl-Y-(C1-6alkyl), or C0-6alkyl-Y-(C0-6alkyl)-(C3-7cycloalkyl)-(C0-6alkyl); R2 is (un)substituted alkyl-Ph or alkyl-heterocycle; R3 is (un)substituted alkyl-heterocycle; R4 is H, OH, or alkyl, etc.; R5 and R6 are independently selected from H, OH, alkyl, or alkylhydroxy, etc.; R7 is H, alkyl, benzyl, Ph, etc.; Y is a single bond, -O-, -S-, or -S(O)-, etc.; n = 0, 1], useful as modulators of chemokine receptor activity. In particular, these compds. are useful as modulators of the chemokine receptor CCR-2. For instance, cis-pyrimidine derivative II (CCR2 receptor binding IC50 < 1uM) was prepared via reductive amination of the prepared ketone intermediate III by 4-(5-pyrimidyl)piperidine·HCl in the presence of sodium triacetoxyborohydride, and subsequent isomer separation (example 1).

IT 690262-06-7P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(intermediate; preparation of heteroarylpiperidine derivs. useful as modulators of chemokine receptor activity)

RN 690262-06-7 CAPLUS
CN Cyclopentanecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-3-[4-(6-chloro-4-pyrimidinyl)-1-piperidinyl]-1-(1-methylethyl)-, (1R,3S)-rel- (CA INDEX NAME)

Relative stereochemistry.



IT 690262-04-5P 690262-05-6P 690262-07-8P
690262-09-9P 690262-03-0P 690262-10-3P
690262-11-4P 690262-12-5P 690262-13-6P
690262-14-7P 690262-15-8P 690262-16-9P
690262-17-0P 690262-18-1P 690262-19-2P
690262-20-5P 690262-21-6P 690262-22-7P
690262-23-8P 690262-24-9P 690262-25-0P







RN 690262-65-9 CAPLUS
CN Cyclopentanecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-1-(1-methylethyl)-3-[4-(4-thiazolyl)-1-piperidinyl]-, (1R,3S)-rel- (CA INDEX NAME)

Relative stereochemistry.



L8 ANSWER 8 OF 23 CAPLUS COPYRIGHT 2008 ACS on STN
2004:569539 Document No. 141:123573 Preparation of (hetero)arylcarboxamides as factor Xa inhibitors. Liebeschuetz, John Walter; Sheehan, Scott Martin; Watson, Brian Morgan (Eli Lilly and Company, USA). PCT Int. Appl. WO 2004060872 A1 20040722, 75 pp. DESIGNATED STATES: W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW; RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, CY, DE, DK, ES, FI, FR, GA, GB, GR, IE, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN, TD, TG, TR. (English). CODEN: PIXXD2. APPLICATION: WO 2003-US39101 20031222. PRIORITY: US 2002-436625P 20021230.

GI





690262-26-1P 690262-27-2P 690262-28-3P
690262-29-4P 690262-30-7P 690262-31-8P
690262-32-9P 690262-33-0P 690262-34-1P
690262-35-2P 690262-36-3P 690262-37-4P
690262-38-5P 690262-39-6P 690262-40-9P
690262-41-0P 690262-42-1P 690262-43-2P
690262-44-3P 690262-45-4P 690262-46-5P
690262-47-6P 690262-48-7P 690262-49-8P
690262-50-1P 690262-51-2P 690262-52-3P
690262-53-4P 690262-54-5P 690262-55-6P
690262-56-7P 690262-57-8P 690262-58-9P
690262-59-0P 690262-60-3P 690262-61-4P
690262-62-5P 690262-63-6P 690262-64-7P
690262-65-8P 690262-67-0P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of heteroarylpiperidine derivs. useful as modulators of chemokine receptor activity)

RN 690262-04-5 CAPLUS
CN Cyclopentanecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-1-(1-methylethyl)-3-[4-(5-pyrimidinyl)-1-piperidinyl]-, (1R,3S)-rel- (CA INDEX NAME)

Relative stereochemistry.



RN 690262-05-6 CAPLUS
CN Cyclopentanecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-1-(1-methylethyl)-3-[4-(4-pyrimidinyl)-1-piperidinyl]-, (1R,3S)-rel- (CA INDEX NAME)

Relative stereochemistry.







AB Compds. of formula I [R1 = pyrrolidinyl, (substituted) piperidinyl, (substituted) piperazinyl; R2 = (substituted) Ph, indolyl or benzothiophenyl; R3 = (substituted) Ph, pyridyl, furyl, naphthyl, cycloalkyl, alkyl, etc.; Z = CH2, O, (substituted) NH; n = 1-3] are prepared as inhibitors of the serine protease Factor Xa and are useful in the treatment of thrombotic disorders. Thus, II was prepared in several steps. The prepared compds. had Kass values > 1 x 106 L/mol in the enzyme inhibition assay.

IT 724462-77-5P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of (hetero)arylcarboxamides as factor Xa inhibitors)

RN 724462-77-5 CAPLUS
CN 1H-Indole-6-carboxamide, 3-chloro-N-[(1R)-2-[[1-cyclopentyl-4-piperidinyl]methoxy]-1-phenylethyl]- (CA INDEX NAME)

Absolute stereochemistry.



L8 ANSWER 9 OF 23 CAPLUS COPYRIGHT 2008 ACS on STN
2004:412913 Document No. 140:406745 A preparation of heteroarylpiperidine derivatives useful as modulators of chemokine receptor activity. Goble, Stephen D.; Pasternak, Alexander; Yang, Lihu (Merck & Co., Inc., USA). PCT Int. Appl. WO 2004041777 A2 20040521, 90 pp. DESIGNATED STATES: W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU,







RN 690262-07-8 CAPLUS
CN Cyclopentanecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-1-(1-hydroxy-1-methylethyl)-3-[4-(5-pyrimidinyl)-1-piperidinyl]-, (1R,3S)-rel- (CA INDEX NAME)

Relative stereochemistry.



RN 690262-08-9 CAPLUS
CN Cyclopentanecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-1-(1-methylethyl)-3-[4-(2H-1,2,3-triazol-2-yl)-1-piperidinyl]-, (1R,3S)-rel- (CA INDEX NAME)

Relative stereochemistry.



RN 690262-09-0 CAPLUS
CN Cyclopentanecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-1-(1-methylethyl)-3-[4-(1H-1,2,3-triazol-1-yl)-1-piperidinyl]-, (1R,3S)-rel- (CA INDEX NAME)

Relative stereochemistry.



RN 690262-10-3 CAPLUS
CN Cyclopentanecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-1-(1-methylethyl)-3-[4-(1H-1,2,4-triazol-1-yl)-1-piperidinyl]-, (1R,3S)-rel- (CA INDEX NAME)

Relative stereochemistry.







RN 690262-16-9 CAPLUS
CN Cyclopentanecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-1-(1-methylethyl)-3-[4-(1H-pyrazol-1-yl)-1-piperidinyl]-, (1R,3S)-rel- (CA INDEX NAME)

Relative stereochemistry.



RN 690262-17-0 CAPLUS
CN Cyclopentanecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-1-(1-methylethyl)-3-[4-(4H-1,2,4-triazol-4-yl)-1-piperidinyl]-, (1R,3S)-rel- (CA INDEX NAME)

Relative stereochemistry.



RN 690262-18-1 CAPLUS
CN Cyclopentanecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-1-(1-hydroxy-1-methylethyl)-3-[4-(1H-pyrazol-1-yl)-1-piperidinyl]-, (1R,3S)-rel- (CA INDEX NAME)

Relative stereochemistry.





RN 690262-11-4 CAPLUS
CN Cyclopentanecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-1-(1-methylethyl)-3-[4-(2H-tetrazol-2-yl)-1-piperidinyl]-, (1R,3S)-rel- (CA INDEX NAME)

Relative stereochemistry.



RN 690262-12-5 CAPLUS
CN Cyclopentanecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-1-(1-methylethyl)-3-[4-(1H-tetrazol-1-yl)-1-piperidinyl]-, (1R,3S)-rel- (CA INDEX NAME)

Relative stereochemistry.



RN 690262-13-6 CAPLUS
CN Cyclopentanecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-1-(1-methylethyl)-3-[4-(5-methyl-2H-tetrazol-2-yl)-1-piperidinyl]-, (1R,3S)-rel- (CA INDEX NAME)

Relative stereochemistry.







RN 690262-19-2 CAPLUS
CN Cyclopentanecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-1-(1-hydroxy-1-methylethyl)-3-[4-(1H-imidazol-1-yl)-1-piperidinyl]-, (1R,3S)-rel- (CA INDEX NAME)

Relative stereochemistry.



RN 690262-20-5 CAPLUS
CN Cyclopentanecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-1-(1-hydroxy-1-methylethyl)-3-[4-(2H-1,2,3-triazol-2-yl)-1-piperidinyl]-, (1R,3S)-rel- (CA INDEX NAME)

Relative stereochemistry.







RN 690262-14-7 CAPLUS
CN Cyclopentanecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-3-[4-(1H-imidazol-1-yl)-1-piperidinyl]-1-(1-methylethyl)-, (1R,3S)-rel- (CA INDEX NAME)

Relative stereochemistry.



RN 690262-15-8 CAPLUS
CN Cyclopentanecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-1-(1-methylethyl)-3-[4-(1H-pyrrol-1-yl)-1-piperidinyl]-, (1R,3S)-rel- (CA INDEX NAME)

Relative stereochemistry.









RN 690262-21-6 CAPLUS
CN Cyclopentanecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-1-(1-hydroxy-1-methylethyl)-3-[4-(1H-1,2,3-triazol-1-yl)-1-piperidinyl]-, (1R,3S)-rel- (CA INDEX NAME)

Relative stereochemistry.



RN 690262-22-7 CAPLUS
CN Cyclopentanecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-1-(1-hydroxy-1-methylethyl)-3-[4-(1H-1,2,4-triazol-1-yl)-1-piperidinyl]-, (1R,3S)-rel- (CA INDEX NAME)

Relative stereochemistry.



RN 690262-23-8 CAPLUS
CN Cyclopentanecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-1-[1-hydroxy-1-methylethyl]-3-[4-(1H-tetrazol-1-yl)-1-piperidinyl]-, (1R,3S)-rel- (CA INDEX NAME)

Relative stereochemistry.



RN 690262-24-9 CAPLUS
CN Cyclopentanecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-1-[1-hydroxy-1-methylethyl]-3-[4-(2H-tetrazol-2-yl)-1-piperidinyl]-, (1R,3S)-rel- (CA INDEX NAME)

Relative stereochemistry.





RN 690262-29-4 CAPLUS
CN Cyclopentanecarboxamide, N-[[3-fluoro-5-(trifluoromethyl)phenyl]methyl]-1-(1-methylethyl)-3-[4-(1H-1,2,4-triazol-1-yl)-1-piperidinyl]-, (1R,3S)-rel- (CA INDEX NAME)

Relative stereochemistry.



RN 690262-30-7 CAPLUS
CN Cyclopentanecarboxamide, N-[[3-fluoro-5-(trifluoromethyl)phenyl]methyl]-1-(1-methylethyl)-3-[4-(1H-tetrazol-1-yl)-1-piperidinyl]-, (1R,3S)-rel- (CA INDEX NAME)

Relative stereochemistry.



RN 690262-31-8 CAPLUS
CN Cyclopentanecarboxamide, N-[[3-fluoro-5-(trifluoromethyl)phenyl]methyl]-1-(1-methylethyl)-3-[4-(2H-tetrazol-2-yl)-1-piperidinyl]-, (1R,3S)-rel- (CA INDEX NAME)

Relative stereochemistry.







RN 690262-25-0 CAPLUS
CN Cyclopentanecarboxamide, N-[[3-fluoro-5-(trifluoromethyl)phenyl]methyl]-1-(1-methylethyl)-3-[4-(1H-pyrazol-1-yl)-1-piperidinyl]-, (1R,3S)-rel- (CA INDEX NAME)

Relative stereochemistry.



RN 690262-26-1 CAPLUS
CN Cyclopentanecarboxamide, N-[[3-fluoro-5-(trifluoromethyl)phenyl]methyl]-3-[4-(1H-imidazol-1-yl)-1-piperidinyl]-1-(1-methylethyl)-, (1R,3S)-rel- (CA INDEX NAME)

Relative stereochemistry.







RN 690262-32-9 CAPLUS
CN Cyclopentanecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-3-[4-(1H-indazol-1-yl)-1-piperidinyl]-1-(1-methylethyl)-, (1R,3S)-rel- (CA INDEX NAME)

Relative stereochemistry.



RN 690262-33-0 CAPLUS
CN Cyclopentanecarboxamide, N-[[3-fluoro-5-(trifluoromethyl)phenyl]methyl]-1-(1-hydroxy-1-methylethyl)-3-[4-(1H-pyrazol-1-yl)-1-piperidinyl]-, (1R,3S)-rel- (CA INDEX NAME)

Relative stereochemistry.







RN 690262-27-2 CAPLUS
CN Cyclopentanecarboxamide, N-[[3-fluoro-5-(trifluoromethyl)phenyl]methyl]-1-(1-methylethyl)-3-[4-(2H-1,2,3-triazol-2-yl)-1-piperidinyl]-, (1R,3S)-rel- (CA INDEX NAME)

Relative stereochemistry.



RN 690262-28-3 CAPLUS
CN Cyclopentanecarboxamide, N-[[3-fluoro-5-(trifluoromethyl)phenyl]methyl]-1-(1-methylethyl)-3-[4-(1H-1,2,3-triazol-1-yl)-1-piperidinyl]-, (1R,3S)-rel- (CA INDEX NAME)

Relative stereochemistry.











RN 690262-34-1 CAPLUS
CN Cyclopentanecarboxamide, N-[[3-fluoro-5-(trifluoromethyl)phenyl]methyl]-1-(1-hydroxy-1-methylethyl)-3-[4-(1H-imidazol-1-yl)-1-piperidinyl]-, (1R,3S)-rel- (CA INDEX NAME)

Relative stereochemistry.



RN 690262-35-2 CAPLUS
CN Cyclopentanecarboxamide, N-[[3-fluoro-5-(trifluoromethyl)phenyl]methyl]-1-(1-hydroxy-1-methylethyl)-3-[4-(2H-1,2,3-triazol-2-yl)-1-piperidinyl]-, (1R,3S)-rel- (CA INDEX NAME)

Relative stereochemistry.



RN 690262-36-3 CAPLUS
CN Cyclopentanecarboxamide, N-[[3-fluoro-5-(trifluoromethyl)phenyl]methyl]-1-(1-hydroxy-1-methylethyl)-3-[4-(1H-1,2,3-triazol-1-yl)-1-piperidinyl]-, (1R,3S)-rel- (CA INDEX NAME)

Relative stereochemistry.



RN 690262-37-4 CAPLUS
CN Cyclopentanecarboxamide, N-[[3-fluoro-5-(trifluoromethyl)phenyl]methyl]-1-(1-hydroxy-1-methylethyl)-3-[4-(1H-1,2,4-triazol-1-yl)-1-piperidinyl]-, (1R,3S)-rel- (CA INDEX NAME)

Relative stereochemistry.







RN 690262-38-5 CAPLUS
CN Cyclopentanecarboxamide, N-[[3-fluoro-5-(trifluoromethyl)phenyl]methyl]-1-(1-hydroxy-1-methylethyl)-3-[4-(1H-tetrazol-1-yl)-1-piperidinyl]-, (1R,3S)-rel- (CA INDEX NAME)

Relative stereochemistry.



RN 690262-39-6 CAPLUS
CN Cyclopentanecarboxamide, N-[[3-fluoro-5-(trifluoromethyl)phenyl]methyl]-1-(1-hydroxy-1-methylethyl)-3-[4-(2H-tetrazol-2-yl)-1-piperidinyl]-, (1R,3S)-rel- (CA INDEX NAME)

Relative stereochemistry.







RN 690262-40-9 CAPLUS
CN Cyclopentanecarboxamide, 3-[4-(1H-benzimidazol-1-yl)-1-piperidinyl]-N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-1-(1-methylethyl)-, (1R,3S)-rel- (CA INDEX NAME)

Relative stereochemistry.



RN 690262-41-0 CAPLUS
CN Cyclopentanecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-3-[4-(2,3-dihydro-2-oxo-1H-imidazol-1-yl)-1-piperidinyl]-1-(1-methylethyl)-, (1R,3S)-rel- (CA INDEX NAME)

Relative stereochemistry.







RN 690262-42-1 CAPLUS
CN Cyclopentanecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-3-[4-(1H-imidazol-2-yl)-1-piperidinyl]-1-(1-methylethyl)-, (1R,3S)-rel- (CA INDEX NAME)

Relative stereochemistry.



RN 690262-43-2 CAPLUS
CN Cyclopentanecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-1-(1-methylethyl)-3-[4-(2-thiazolyl)-1-piperidinyl]-, (1R,3S)-rel- (CA INDEX NAME)

Relative stereochemistry.







RN 690262-44-3 CAPLUS
CN Cyclopentanecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-1-(1-methylethyl)-3-[4-(1H-pyrazol-3-yl)-1-piperidinyl]-, (1R,3S)-rel- (CA INDEX NAME)

Relative stereochemistry.



RN 690262-45-4 CAPLUS
CN Cyclopentanecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-1-(1-hydroxy-1-methylethyl)-3-[4-(1-methyl-1H-tetrazol-5-yl)-1-piperidinyl]-, (1R,3S)-rel- (CA INDEX NAME)

Relative stereochemistry.



RN 690262-46-5 CAPLUS
CN Cyclopentanecarboxamide, N-[[3-fluoro-5-(trifluoromethyl)phenyl]methyl]-1-(1-methylethyl)-3-[4-(1H-pyrazol-3-yl)-1-piperidinyl]-, (1R,3S)-rel- (CA INDEX NAME)

Relative stereochemistry.







RN 690262-47-6 CAPLUS
CN Cyclopentanecarboxamide, N-[[3-fluoro-5-(trifluoromethyl)phenyl]methyl]-1-(1-methylethyl)-3-[4-(1-methyl-1H-tetrazol-5-yl)-1-piperidinyl]-, (1R,3S)-rel- (CA INDEX NAME)

Relative stereochemistry.



RN 690262-48-7 CAPLUS
CN Cyclopentanecarboxamide, N-[[3-fluoro-5-(trifluoromethyl)phenyl]methyl]-1-(1-hydroxy-1-methylethyl)-3-[4-(1H-pyrazol-3-yl)-1-piperidinyl]-, (1R,3S)-rel- (CA INDEX NAME)

Relative stereochemistry.



RN 690262-49-6 CAPLUS
CN Cyclopentanecarboxamide, N-[[3-fluoro-5-(trifluoromethyl)phenyl]methyl]-1-(1-hydroxy-1-methylethyl)-3-[4-(1-methyl-1H-tetrazol-5-yl)-1-piperidinyl]-, (1R,3S)-rel- (CA INDEX NAME)

Relative stereochemistry.



RN 690262-50-1 CAPLUS
CN Cyclopentanecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-1-(1-methylethyl)-3-(4-pyrazinyl-1-piperidinyl)-, (1R,3S)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.







RN 690262-56-7 CAPLUS
CN Carbamic acid, [4-[1-[[(1R,3S)-3-[[[3,5-bis(trifluoromethyl)phenyl]methyl]amino]carbonyl]-3-(1-methylethyl)cyclopentyl]-4-piperidinyl]-2-thiazolyl]-, methyl ester, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 690262-57-8 CAPLUS
CN Cyclopentanecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-1-(1-methylethyl)-3-[4-[2-[(methylsulfonyl)amino]-4-thiazolyl]-1-piperidinyl]-, (1R,3S)-rel- (CA INDEX NAME)

Relative stereochemistry.









RN 690262-51-2 CAPLUS
CN Cyclopentanecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-1-(1-methylethyl)-3-[4-(2-pyrimidinyl)-1-piperidinyl]-, (1R,3S)-rel- (CA INDEX NAME)

Relative stereochemistry.



RN 690262-52-3 CAPLUS
CN Cyclopentanecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-3-[4-(6-chloro-3-pyridazinyl)-1-piperidinyl]-1-(1-methylethyl)-, (1R,3S)-rel- (CA INDEX NAME)

Relative stereochemistry.







RN 690262-58-9 CAPLUS
CN Cyclopentanecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-3-[4-(2,5-dihydro-5-oxo-1,2,4-thiadiazol-3-yl)-1-piperidinyl]-1-(1-methylethyl)-, (1R,3S)-rel- (CA INDEX NAME)

Relative stereochemistry.



RN 690262-59-0 CAPLUS
CN Cyclopentanecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-1-(1-methylethyl)-3-[4-(4H-pyrazol-4-yl)-1-piperidinyl]-, (1R,3S)-rel- (CA INDEX NAME)

Relative stereochemistry.



RN 690262-60-3 CAPLUS
CN Cyclopentanecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-1-(1-methylethyl)-3-[4-(3-pyridinyl)-1-piperidinyl]-, (1R,3S)-rel- (CA INDEX NAME)

Relative stereochemistry.





RN 690262-53-4 CAPLUS
CN Cyclopentanecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-1-(1-methylethyl)-3-[4-(3-pyridazinyl)-1-piperidinyl]-,, (1R,3S)-rel- (CA INDEX NAME)

Relative stereochemistry.



RN 690262-54-5 CAPLUS
CN Cyclopentanecarboxamide, 3-[4-(2-amino-4-thiazolyl)-1-piperidinyl]-N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-1-(1-methylethyl)-, (1R,3S)-rel- (CA INDEX NAME)

Relative stereochemistry.



RN 690262-55-6 CAPLUS
CN Cyclopentanecarboxamide, 3-[4-[2-(acetylamino)-4-thiazolyl]-1-piperidinyl]-N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-1-(1-methylethyl)-, (1R,3S)-rel- (CA INDEX NAME)

Relative stereochemistry.







RN 690262-61-4 CAPLUS
CN Cyclopentanecarboxamide, 3-[4-[2-(acetylamino)-5-thiazolyl]-1-piperidinyl]-N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-1-(1-methylethyl)-, (1R,3S)-rel- (CA INDEX NAME)

Relative stereochemistry.



RN 690262-62-5 CAPLUS
CN Carbamic acid, [5-[1-[(1R,3S)-3-[[[[3,5-bis(trifluoromethyl)phenyl]methyl]amino]carbonyl]-3-(1-methylethyl)cyclopentyl]-4-piperidinyl]-2-thiazolyl]-, phenylmethyl ester, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 690262-63-6 CAPLUS
CN Cyclopentanecarboxamide, 3-[4-(2-amino-5-thiazolyl)-1-piperidinyl]-N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-1-(1-methylethyl)-, (1R,3S)-rel- (CA INDEX NAME)

Relative stereochemistry.



RN 690262-64-7 CAPLUS
CN Cyclopentanecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-1-(1-methylethyl)-3-[4-(4-pyridazinyl)-1-piperidinyl]-, (1R,3S)-rel- (CA INDEX NAME)

Relative stereochemistry.







RN 400771-19-9 CAPLUS
CN Cyclopentanecarboxamide, 1-cyano-3-[4-(4-fluorophenyl)-1-piperidinyl]-N-[[3-fluoro-5-(trifluoromethyl)phenyl]methyl]-, (1R,3S)-rel- (CA INDEX NAME)

Relative stereochemistry.



RN 690653-54-4 CAPLUS
CN Cyclopentanecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-1-phenyl-3-(4-phenyl-1-piperidinyl)-, (1R,3S)-rel- (CA INDEX NAME)

Relative stereochemistry.



RN 690653-55-5 CAPLUS







RN 690262-65-8 CAPLUS
CN Cyclopentanecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-1-(1-methylethyl)-3-[4-(4-thiazolyl)-1-piperidinyl]-, (1R,3S)-rel- (CA INDEX NAME)

Relative stereochemistry.



RN 690262-67-0 CAPLUS
CN Cyclopentanecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-1-(1-methylethyl)-3-[3-methyl-4-(1H-pyrazol-1-yl)-1-piperidinyl]- (CA INDEX NAME)



L8 ANSWER 10 OF 23 CAPLUS COPYRIGHT 2008 ACS on STN
2004:412749 Document No. 140:423705 A preparation of piperidinylcyclopentyl amide derivatives, useful as modulators of chemokine receptor activity.





CN Cyclopentanecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-1-phenyl-3-(4-phenyl-1-piperidinyl)-, (1R,3R)-rel- (CA INDEX NAME)

Relative stereochemistry.



RN 690653-56-6 CAPLUS
CN Cyclopentanecarboxamide, N-[[3-fluoro-5-(trifluoromethyl)phenyl]methyl]-1-phenyl-3-(4-phenyl-1-piperidinyl)-, (1R,3S)-rel- (CA INDEX NAME)

Relative stereochemistry.



RN 690653-57-7 CAPLUS
CN Cyclopentanecarboxamide, N-[[3-fluoro-5-(trifluoromethyl)phenyl]methyl]-1-phenyl-3-(4-phenyl-1-piperidinyl)-, (1R,3R)-rel- (CA INDEX NAME)

Relative stereochemistry.



RN 690653-58-7 CAPLUS
CN Cyclopentanecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-N-methyl-1-phenyl-3-(4-phenyl-1-piperidinyl)-, (1R,3S)-rel- (CA INDEX NAME)





Zhou, Changyou; Pasternak, Alexander; Yang, Lihu (Merck & Co., Inc., USA). PCT Int. Appl. WO 2004041163 A2 20040521, 100 pp. DESIGNATED STATES: W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW; RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, CY, DE, DK, ES, FI, FR, GA, GB, GR, IE, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN, TD, TG, TR. (English). CODEN: PIXXD2. APPLICATION: WO 2003-US34099 20031024. PRIORITY: US 2002-422381P 20021030.

GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB The invention relates to piperidinylcyclopentyl amide derivs. of formula I [wherein: X is -O-, -CH2O-, -CO2-, or -OC(O)-, etc.; W is (un)substituted Ph or heterocycle; Z is C, N, or O, wherein when Z is N, then R4 is absent, and when W is O, then both R3 and R4 are absent; n = 0-4; R1 is H, halo, trifluoromethyl, OH, alkyl, or CN, etc.; R2 is (un)substituted C0-6alkyl-(phenyl/heterocycle); R3 is (un)substituted C0-6alkyl-phenyl; R4 is H, OH, CN, or alkyl, etc.; R5 and R6 are independently selected from H, OH, alkyl, alkoxy, or oxo, etc.; R3 and R5 or R4 and R6 may be joined together to form (un)substituted ring] , useful as modulators of chemokine receptor activity. In particular, these compds. are useful as modulators of the chemokine receptor CCR-2. For instance, piperidinylcyclopentyl amide derivative II (CCR-2 receptor binding IC50 < 1μM) was prepared via amination of the obtained intermediate cyclopentanone derivative III by 4-(4-fluorophenyl)piperidine with a yield of 66% (example 1).

IT 400771-18-8P 400771-19-9P 690653-54-4P
690653-55-5P 690653-56-6P 690653-57-7P
690653-58-8P 690653-59-9P 690653-66-8P
690653-67-9P 690653-68-0P 690653-69-1P
690653-75-9P 690653-85-1P 690654-01-4P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(intermediate; preparation of piperidinylcyclopentyl amide derivs., useful as modulators of chemokine receptor activity)

RN 400771-18-8 CAPLUS
CN Cyclopentanecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-1-cyano-3-[4-(4-fluorophenyl)-1-piperidinyl]-, (1R,3S)-rel- (CA INDEX NAME)

Relative stereochemistry.





Relative stereochemistry.



RN 690653-59-9 CAPLUS
CN Cyclopentanecarboxamide, 1-(3,4-dichlorophenyl)-3-(4-phenyl-1-piperidinyl)-N-[[3-(trifluoromethyl)phenyl]methyl]- (CA INDEX NAME)



RN 690653-66-6 CAPLUS
CN 1,1-Cyclopentanedicarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-3-[4-(4-fluorophenyl)-1-piperidinyl]-, (1R,3S)-rel- (CA INDEX NAME)

Relative stereochemistry.



RN 690653-67-9 CAPLUS
CN Cyclopentanecarboxamide, 3-[4-(4-fluorophenyl)-1-piperidinyl]-N-[[3-fluoro-5-(trifluoromethyl)phenyl]methyl]-1-(1H-tetrazol-5-yl)-, (1R,3S)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 690653-68-0 CAPLUS
CN Cyclopentanecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-3-[4-(4-fluorophenyl)-1-piperidinyl]-1-[(hydroxyamino)iminomethyl]-, (1R,3S)-rel- (CA INDEX NAME)

Relative stereochemistry.



RN 690653-69-1 CAPLUS
CN Cyclopentanecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-3-[4-(4-fluorophenyl)-1-piperidinyl]-1-(1H-tetrazol-5-yl)-, (1R,3S)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.





dihydro-5-oxo-1,2,4-oxadiazol-3-yl)-3-[4-(4-fluorophenyl)-1-piperidinyl]-, (1R,3S)-rel- (CA INDEX NAME)

Relative stereochemistry.



RN 690653-95-3 CAPLUS
CN Cyclopentanecarboxamide, 1-(2-amino-4-thiazolyl)-N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-3-[4-(4-fluorophenyl)-1-piperidinyl]-, (1R,3S)-rel- (CA INDEX NAME)

Relative stereochemistry.



IT 690653-28-2P 690653-33-9P 690653-34-0P
690653-35-1P 690653-36-2P 690653-37-3P
690653-38-4P 690653-39-5P 690653-40-8P
690653-41-9P 690653-60-2P 690653-61-3P
690653-62-4P 690653-63-5P 690653-64-6P
690653-65-7P 690653-70-4P 690653-71-5P
690653-72-6P 690653-73-7P 690653-74-8P
690653-76-0P 690653-77-1P 690653-78-2P
690653-79-3P 690653-80-6P 690653-81-7P
690653-82-8P 690653-84-0P 690653-96-4P
690653-97-5P 690653-98-6P 690653-99-7P
690654-00-2P 690654-02-5P 690654-03-6P
690654-05-8P 690654-06-9P 690654-07-0P
690654-08-1P 690654-11-6P 690654-12-7P
690654-13-8P 690654-14-9P 690654-15-0P







RN 690653-75-9 CAPLUS
CN 2H-Tetrazole-2-acetic acid, 5-[(1R,3S)-1-[[[[3,5-bis(trifluoromethyl)phenyl]methyl]amino]carbonyl]-3-[4-(4-fluorophenyl)-1-piperidinyl]cyclopentyl]-, rel- (CA INDEX NAME)

Relative stereochemistry.



RN 690653-85-1 CAPLUS
CN Carbamic acid, [4-[(1R,3S)-1-[[[[3,5-bis(trifluoromethyl)phenyl]methyl]amino]carbonyl]-3-[4-(4-fluorophenyl)-1-piperidinyl]cyclopentyl]-2-thiazolyl]-, 1,1-dimethylethyl ester, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.





690654-16-1P 690654-17-2P 690654-18-3P
690654-19-4P 690654-20-7P 690654-21-8P
690654-24-1P 690654-25-2P 690654-26-3P
690654-27-4P 690655-04-0P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of piperidinylcyclopentyl amide derivs., useful as modulators of chemokine receptor activity)
RN 690653-28-2 CAPLUS
CN Cyclopentanecarboxamide, 1-(3-fluorophenyl)-3-[4-(4-fluorophenyl)-1-piperidinyl]-N-[[3-fluoro-5-(trifluoromethyl)phenyl]methyl]- (CA INDEX NAME)



RN 690653-33-9 CAPLUS
CN Cyclopentanecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-1-(3-fluorophenyl)-3-[4-(4-fluorophenyl)-1-piperidinyl]- (CA INDEX NAME)



RN 690653-34-0 CAPLUS
CN Cyclopentanecarboxamide, 3-[4-(4-fluorophenyl)-1-piperidinyl]-N-[[3-fluoro-5-(trifluoromethyl)phenyl]methyl]-1-(3-methoxyphenyl)- (CA INDEX NAME)



RN 690653-35-1 CAPLUS
CN Cyclopentanecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-3-[4-(4-fluorophenyl)-1-piperidinyl]-1-(3-methoxyphenyl)- (CA INDEX NAME)







RN 690654-01-4 CAPLUS
CN Carbamic acid, [4-[(1R,3S)-1-[[[1-[3,5-bis(trifluoromethyl)phenyl]ethyl]amino]carbonyl]-3-[4-(4-fluorophenyl)-1-piperidinyl]cyclopentyl]-2-thiazolyl]-, 1,1-dimethylethyl ester, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



IT 690653-83-9P 690653-95-3P
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(preparation of piperidinylcyclopentyl amide derivs., useful as modulators of chemokine receptor activity)
RN 690653-83-9 CAPLUS
CN Cyclopentanecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-1-(2,5-







RN 690653-36-2 CAPLUS
CN Cyclopentanecarboxamide, 3-[4-(4-fluorophenyl)-1-piperidinyl]-N-[[3-fluoro-5-(trifluoromethyl)phenyl]methyl]-1-(2-thienyl)- (CA INDEX NAME)



RN 690653-37-3 CAPLUS
CN Cyclopentanecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-3-[4-(4-fluorophenyl)-1-piperidinyl]-1-(2-thienyl)- (CA INDEX NAME)



RN 690653-38-4 CAPLUS
CN Cyclopentanecarboxamide, 3-[4-(4-fluorophenyl)-1-piperidinyl]-N-[[3-fluoro-5-(trifluoromethyl)phenyl]methyl]-1-(3-thienyl)- (CA INDEX NAME)



RN 690653-39-5 CAPLUS
CN Cyclopentanecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-3-[4-(4-fluorophenyl)-1-piperidinyl]-1-(3-thienyl)- (CA INDEX NAME)



RN 690653-40-8 CAPLUS
CN Cyclopentanecarboxamide, 3-[4-(4-fluorophenyl)-1-piperidinyl]-N-[[3-fluoro-5-(trifluoromethyl)phenyl]methyl]-1-phenyl- (CA INDEX NAME)



RN 690653-41-9 CAPLUS
CN Cyclopentanecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-3-[4-(4-fluorophenyl)-1-piperidinyl]-1-phenyl- (CA INDEX NAME)



RN 690653-60-2 CAPLUS
CN Cyclopentanecarboxamide, 1-(3,4-dichlorophenyl)-3-(4-phenyl-1-piperidinyl)-N-[[2-(trifluoromethyl)phenyl]methyl]- (CA INDEX NAME)



RN 690653-61-3 CAPLUS
CN Cyclopentanecarboxamide, 1-(3,4-dichlorophenyl)-3-(4-phenyl-1-piperidinyl)-N-[[4-(trifluoromethyl)phenyl]methyl]- (CA INDEX NAME)







RN 690653-72-6 CAPLUS
CN 2H-Tetrazole-2-acetic acid, 5-[(1R,3S)-1-[[[[3,5-bis(trifluoromethyl)phenyl]methyl]amino]carbonyl]-3-[4-(4-fluorophenyl)-1-piperidinyl]cyclopentyl]-, methyl ester, rel- (CA INDEX NAME)

Relative stereochemistry.



RN 690653-73-7 CAPLUS
CN Cyclopentanecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-1-(2-ethyl-2H-tetrazol-5-yl)-3-[4-(4-fluorophenyl)-1-piperidinyl]-, (1R,3S)-rel- (CA INDEX NAME)

Relative stereochemistry.







RN 690653-62-4 CAPLUS
CN Cyclopentanecarboxamide, 1-(3,4-dichlorophenyl)-N-[(3,5-dichlorophenyl)methyl]-3-(4-phenyl-1-piperidinyl)- (CA INDEX NAME)



RN 690653-63-5 CAPLUS
CN Cyclopentanecarboxamide, 1-(3,4-dichlorophenyl)-N-[(3,4-dichlorophenyl)methyl]-3-(4-phenyl-1-piperidinyl)- (CA INDEX NAME)



RN 690653-64-6 CAPLUS
CN Cyclopentanecarboxamide, N-[1-[3,5-bis(trifluoromethyl)phenyl]ethyl]-1-(3,4-dichlorophenyl)-3-(4-phenyl-1-piperidinyl)- (CA INDEX NAME)







RN 690653-65-7 CAPLUS
CN Cyclopentanecarboxamide, 1-(3,4-dichlorophenyl)-3-(4-phenyl-1-piperidinyl)-N-[1-[3-(trifluoromethyl)phenyl]ethyl]- (CA INDEX NAME)



RN 690653-70-4 CAPLUS
CN Cyclopentanecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-3-[4-(4-fluorophenyl)-1-piperidinyl]-1-(2-methyl-2H-tetrazol-5-yl)-, (1R,3S)-rel- (CA INDEX NAME)

Relative stereochemistry.



RN 690653-71-5 CAPLUS
CN Cyclopentanecarboxamide, 3-[4-(4-fluorophenyl)-1-piperidinyl]-N-[[3-fluoro-5-(trifluoromethyl)phenyl]methyl]-1-(2-methyl-2H-tetrazol-5-yl)-, (1R,3S)-rel- (CA INDEX NAME)

Relative stereochemistry.







RN 690653-74-8 CAPLUS
CN Cyclopentanecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-3-[4-(4-fluorophenyl)-1-piperidinyl]-1-[2-(1-methylethyl)-2H-tetrazol-5-yl]-, (1R,3S)-rel- (CA INDEX NAME)

Relative stereochemistry.



RN 690653-76-0 CAPLUS
CN 2H-Tetrazole-2-acetamide, 5-[(1R,3S)-1-[[[[3,5-bis(trifluoromethyl)phenyl]methyl]amino]carbonyl]-3-[4-(4-fluorophenyl)-1-piperidinyl]cyclopentyl]-N-methyl-, rel- (CA INDEX NAME)

Relative stereochemistry.







RN 690653-77-1 CAPLUS
CN 2H-Tetrazole-2-acetamide, 5-[(1R,3S)-1-[[[[3,5-bis(trifluoromethyl)phenyl]methyl]amino]carbonyl]-3-[4-(4-fluorophenyl)-1-piperidinyl]cyclopentyl]-N,N-dimethyl-, rel- (CA INDEX NAME)

Relative stereochemistry.



RN 690653-78-2 CAPLUS
CN Cyclopentanecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-3-[4-(4-fluorophenyl)-1-piperidinyl]-1-(1,2,4-oxadiazol-5-yl)-, (1R,3S)-rel- (CA INDEX NAME)

Relative stereochemistry.



RN 690653-79-3 CAPLUS
CN Cyclopentanecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-3-[4-(4-fluorophenyl)-1-piperidinyl]-1-(1-methyl-1H-1,2,4-triazol-5-yl)-, (1R,3S)-rel- (CA INDEX NAME)

Relative stereochemistry.



RN 690653-80-6 CAPLUS
CN Cyclopentanecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-3-[4-(4-fluorophenyl)-1-piperidinyl]-1-(1-methyl-1H-1,2,4-triazol-3-yl)-, (1R,3S)-rel- (CA INDEX NAME)

Relative stereochemistry.







RN 690653-35-6 CAPLUS
CN Cyclopentanecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-3-[4-(4-fluorophenyl)-1-piperidinyl]-1-[2-[(methylsulfonyl)amino]-4-thiazolyl]-, (1R,3S)-rel- (CA INDEX NAME)

Relative stereochemistry.



RN 690653-93-7 CAPLUS
CN Cyclopentanecarboxamide, 1-[2-[(aminoiminomethyl)amino]-4-thiazolyl]-N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-3-[4-(4-fluorophenyl)-1-piperidinyl]-, (1R,3S)-rel- (CA INDEX NAME)

Relative stereochemistry.







RN 690653-81-7 CAPLUS
CN Cyclopentanecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-3-[4-(4-fluorophenyl)-1-piperidinyl]-1-(5-methyl-1,2,4-oxadiazol-3-yl)-, (1R,3S)-rel- (CA INDEX NAME)

Relative stereochemistry.



RN 690653-82-8 CAPLUS
CN Cyclopentanecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-3-[4-(4-fluorophenyl)-1-piperidinyl]-1-(1,2,4-oxadiazol-3-yl)-, (1R,3S)-rel- (CA INDEX NAME)

Relative stereochemistry.









RN 690654-00-3 CAPLUS
CN Cyclopentanecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-3-[4-(4-fluorophenyl)-1-piperidinyl]-1-[2-[[(methylamino)carbonyl]amino]-4-thiazolyl]-, (1R,3S)-rel- (CA INDEX NAME)

Relative stereochemistry.



RN 690654-02-5 CAPLUS
CN Cyclopentanecarboxamide, 1-(2-amino-4-thiazolyl)-N-[1-[3,5-bis(trifluoromethyl)phenyl]ethyl]-3-[4-(4-fluorophenyl)-1-piperidinyl]-, (1R,3S)-rel- (CA INDEX NAME)

Relative stereochemistry.





RN 690653-84-0 CAPLUS
CN Cyclopentanecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-1-(4,5-dihydro-4-methyl-5-oxo-1,2,4-oxadiazol-3-yl)-3-[4-(4-fluorophenyl)-1-piperidinyl]-, (1R,3S)-rel- (CA INDEX NAME)

Relative stereochemistry.



RN 690653-96-4 CAPLUS
CN Cyclopentanecarboxamide, 1-[2-(acetylamino)-4-thiazolyl]-N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-3-[4-(4-fluorophenyl)-1-piperidinyl]-, (1R,3S)-rel- (CA INDEX NAME)

Relative stereochemistry.



RN 690653-97-5 CAPLUS
CN Carbamic acid, [4-[(1R,3S)-1-[[[3,5-bis(trifluoromethyl)phenyl]methyl]amino]carbonyl]-3-[4-(4-fluorophenyl)-1-piperidinyl]cyclopentyl]-2-thiazolyl]-, methyl ester, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.







RN 690654-03-6 CAPLUS
CN Cyclopentanecarboxamide, 1-[2-(acetylamino)-4-thiazolyl]-N-[1-[3,5-bis(trifluoromethyl)phenyl]ethyl]-3-[4-(4-fluorophenyl)-1-piperidinyl]-, (1R,3S)-rel- (CA INDEX NAME)

Relative stereochemistry.



RN 690654-05-8 CAPLUS
CN Cyclopentanecarboxamide, 1-(2-amino-4-thiazolyl)-N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-3-(4-phenyl-1-piperidinyl)-, (1R,3S)-rel- (CA INDEX NAME)

Relative stereochemistry.



RN 690654-06-9 CAPLUS
CN Cyclopentanecarboxamide, 1-[2-(acetylamino)-4-thiazolyl]-N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-3-(4-phenyl-1-piperidinyl)-, (1R,3S)-rel- (CA INDEX NAME)

Relative stereochemistry.



RN 690654-07-0 CAPLUS
CN Cyclopentanecarboxamide, 1-(2-amino-4-thiazolyl)-N-[(3-fluoro-5-(trifluoromethyl)phenyl]methyl]-3-(4-phenyl-1-piperidinyl)-, (1R,3S)-rel- (CA INDEX NAME)

Relative stereochemistry.



RN 690654-08-1 CAPLUS
CN Cyclopentanecarboxamide, 1-[2-(acetylamino)-4-thiazolyl]-N-[[3-fluoro-5-







RN 690654-15-0 CAPLUS
CN Cyclopentanecarboxamide, 1-(2-amino-4-thiazolyl)-N-[1-[3,5-bis(trifluoromethyl)phenyl]ethyl]-3-(1-piperidinyl)-, (1R,3S)-rel- (CA INDEX NAME)

Relative stereochemistry.



RN 690654-16-1 CAPLUS
CN Cyclopentanecarboxamide, 1-[2-(acetylamino)-4-thiazolyl]-N-[1-[3,5-bis(trifluoromethyl)phenyl]ethyl]-3-(1-piperidinyl)-, (1R,3S)-rel- (CA INDEX NAME)

Relative stereochemistry.





(trifluoromethyl)phenyl]methyl]-3-(4-phenyl-1-piperidinyl)-, (1R,3S)-rel- (CA INDEX NAME)

Relative stereochemistry.



RN 690654-11-6 CAPLUS
CN Cyclopentanecarboxamide, 1-(2-amino-4-thiazolyl)-N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-3-(1-piperidinyl)-, (1R,3S)-rel- (CA INDEX NAME)

Relative stereochemistry.



RN 690654-12-7 CAPLUS
CN Cyclopentanecarboxamide, 1-[2-(acetylamino)-4-thiazolyl]-N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-3-(1-piperidinyl)-, (1R,3S)-rel- (CA INDEX NAME)

Relative stereochemistry.







RN 690654-17-2 CAPLUS
CN Cyclopentanecarboxamide, 1-(2-amino-4-thiazolyl)-N-[1-[3,5-bis(trifluoromethyl)phenyl]ethyl]-3-(4-phenyl-1-piperidinyl)-, (1R,3S)-rel- (CA INDEX NAME)

Relative stereochemistry.



RN 690654-18-3 CAPLUS
CN Cyclopentanecarboxamide, 1-[2-(acetylamino)-4-thiazolyl]-N-[1-[3,5-bis(trifluoromethyl)phenyl]ethyl]-3-(4-phenyl-1-piperidinyl)-, (1R,3S)-rel- (CA INDEX NAME)

Relative stereochemistry.









RN 690654-13-8 CAPLUS
CN Benzamide, N-[4-[[(1R,3S)-1-[[[[3,5-bis(trifluoromethyl)phenyl]methyl]amino]carbonyl]-3-(1-piperidinyl)cyclopentyl]-2-thiazolyl]-, rel- (CA INDEX NAME)

Relative stereochemistry.



RN 690654-14-9 CAPLUS
CN Carbamic acid, [4-[(1R,3S)-1-[[[[3,5-bis(trifluoromethyl)phenyl]methyl]amino]carbonyl]-3-(1-piperidinyl)cyclopentyl]-2-thiazolyl]-, phenylmethyl ester, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 690654-19-4 CAPLUS
CN Cyclopentanecarboxamide, 1-(2-amino-4-thiazolyl)-N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-N-methyl-3-(4-phenyl-1-piperidinyl)-, (1R,3S)-rel- (CA INDEX NAME)

Relative stereochemistry.



RN 690654-20-7 CAPLUS
CN Cyclopentanecarboxamide, 1-[2-(acetylamino)-4-thiazolyl]-N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-N-methyl-3-(4-phenyl-1-piperidinyl)-, (1R,3S)-rel- (CA INDEX NAME)

Relative stereochemistry.



RN 690654-21-8 CAPLUS
CN Carbamic acid, [4-[(1R,3S)-1-[[[[3,5-bis(trifluoromethyl)phenyl]methyl]methylamino]carbonyl]-3-(4-phenyl-1-piperidinyl)cyclopentyl]-2-thiazolyl]-, methyl ester, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 690654-24-1 CAPLUS
CN Cyclopentanecarboxamide, 1-(2-amino-4-thiazolyl)-N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-3-[4-(4-fluorophenyl)-1-piperidinyl]-N-methyl-, (1R,3S)-rel- (CA INDEX NAME)

Relative stereochemistry.



RN 690654-25-2 CAPLUS
CN Cyclopentanecarboxamide, 1-[2-(acetylamino)-4-thiazolyl]-N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-3-[4-(4-fluorophenyl)-1-piperidinyl]-N-methyl-, (1R,3S)-rel- (CA INDEX NAME)

Relative stereochemistry.







AB The invention relates to combinatorial libraries containing two or more novel piperidine-3-carboxamide derivative compds. I [wherein X = N or O; R1 = substituted heteroaryl, cycloalkyl, or Ph; R2 = H, OH, halo, or (un)substituted alkylthio, alkylnitrile, (cyclo)alkyl, alkoxy, alkenyl, alkynyl, Ph, naphthyl, PhO, heterocyclyl, or cycloalkylene; R3 and R4 = independently H, OH, or (un)substituted alkylthio, alkylnitrile, (cyclo)alkyl, alkenyl, alkoxy, hydroxyalkyl, Ph, PhO, or heterocyclyl; R5 = H or NH2; R6 = (un)substituted Ph or heterocyclyl] and methods of preparing them. The methods involve loading an aldehyde or diamine on a resin, reacting the resin-bound aldehyde with an amine or reacting the resin-bound diamine with an aldehyde to form an imine, cyclizing the imine to produce a carboxylic acid, acylating the acid, and cleaving and extracting the piperidine-3-carboxamide derivative from the resin. Thus, a combinatorial library of invention compds. (e.g., II) was prepared and screened for antimicrobial activity. Three hundred seventy compds. showed 50% to 99.97% inhibition against Streptococcus pyogenes. Bioassays for binding to human melanocortin receptors and treatment of sexual dysfunction (penile erection in male rats) are also provided.

IT 597569-36-0P
RL: CPN (Combinatorial preparation); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); COMB (Combinatorial study); PREP (Preparation); USES (Uses)
(drug candidate; preparation of combinatorial libraries of piperidinecarboxamide melanocortin receptor ligands for treatment of bacterial infections and sexual dysfunction)

RN 597569-36-0 CAPLUS
CN 3-Piperidinecarboxamide, 1-cyclopentyl-N-[(4-fluorophenyl)methyl]-2-(3-hydroxyphenyl)-6-oxo-3-phenyl- (CA INDEX NAME)









RN 690654-26-3 CAPLUS
CN Glycine, N-[[(1R,3S)-1-(2-amino-4-thiazolyl)-3-(4-phenyl-1-piperidinyl)cyclopentyl]carbonyl]-N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-, ethyl ester, rel- (CA INDEX NAME)

Relative stereochemistry.



RN 690654-27-4 CAPLUS
CN Glycine, N-[[(1R,3S)-1-[2-(acetylamino)-4-thiazolyl]-3-(4-phenyl-1-piperidinyl)cyclopentyl]carbonyl]-N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-, ethyl ester, rel- (CA INDEX NAME)

Relative stereochemistry.





L8 ANSWER 12 OF 23 CAPLUS COPYRIGHT 2008 ACS on STN
2003:485869 Document No. 139:261547 A four component coupling strategy for the synthesis of D-phenylglycinamide-derived non-covalent factor Xa inhibitors. Sheehan, Scott M.; Masters, John J.; Wiley, Michael R.; Young, Stephen C.; Liebeschuetz, John W.; Jones, Stuart D.; Murray, Christopher W.; Franciskovich, Jeffrey B.; Engel, David B.; Weber, Wayne W.; Marimuthu, Jothirajah; Kyle, Jeffrey A.; Smallwood, Jeffrey K.; Farman, Mark W.; Smith, Gerald F. (Lilly Research Laboratories, A Division of Eli Lilly and Company, Indianapolis, IN, 46285, USA). Bioorganic & Medicinal Chemistry Letters, 13(14), 2255-2259 (English) 2003. CODEN: BMCLE8. ISSN: 0960-894X. OTHER SOURCES: CASREACT 139:261547. Publisher: Elsevier Science B.V..

GI



AB A novel isonitrile derivative I (Boc = tert-butoxycarbonyl) was synthesized and used in an Ugi four component coupling reaction for the synthesis of D-phenylglycinamide derivs. as reversible factor Xa inhibitors. The aryl group substitution effects on inhibition of the coagulation cascade serine protease factor Xa was evaluated.

IT 380899-68-3P 380900-25-4P 380900-27-6P
RL: BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(synthesis of phenylglycinamides as coagulation cascade serine protease factor Xa inhibitors by Ugi four component coupling starting from prepared isonitrile)

RN 380899-68-3 CAPLUS
CN 1H-Indole-6-carboxamide, 3-chloro-N-[(1R)-2-[[(1-cyclopentyl-4-piperidinyl)methyl]amino]-2-oxo-1-phenylethyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 380900-25-4 CAPLUS
CN 1H-Indole-6-carboxamide, 3-chloro-N-[2-[[(1-cyclopentyl-4-piperidinyl)methyl]amino]-1-(2-naphthalenyl)-2-oxoethyl]- (CA INDEX NAME)







RN 690655-04-0 CAPLUS
CN Cyclopentanecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-3-[4-(4-fluorophenyl)-1-piperidinyl]-1-(1H-1,2,4-triazol-3-yl)-, (1R,3S)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



L8 ANSWER 11 OF 23 CAPLUS COPYRIGHT 2008 ACS on STN
2003:717796 Document No. 139:245904 Preparation of combinatorial libraries of 1,2-disubstituted-6-oxo-3-phenyl-piperidine-3-carboxamide melanocortin receptor ligands. Kahl, Jeffrey D.; Hebert, Normand (USA). U.S. Pat. Appl. Publ. US 2003171588 A1 20030911, 124 pp. (English). CODEN: USXXCO. APPLICATION: US 2002-91585 20020307.

GI







RN 380900-27-6 CAPLUS
CN 1H-Indole-6-carboxamide, 3-chloro-N-[2-[[(1-cyclopentyl-4-piperidinyl)methyl]amino]-1-(1-naphthalenyl)-2-oxoethyl]- (CA INDEX NAME)



L8 ANSWER 13 OF 23 CAPLUS COPYRIGHT 2008 ACS on STN
2002:555463 Document No. 137:125084 Preparation of substituted ureas as MCH antagonists useful in the treatment of obesity. McBriar, Mark D.; Palani, Anandan; Shapiro, Sherry A.; Xu, Ruo; Clader, John (Schering Corporation, USA). PCT Int. Appl. WO 2002057233 A1 20020725, 106 pp. DESIGNATED STATES: W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, HR, HU, ID, IL, IN, IS, JP, KG, KR, KZ, LC, LK, LR, LT, LU, LV, MA, MD, MG, MK, MN, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, VN, YU, ZA, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM; RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, CY, DE, DK, ES, FI, FR, GA, GB, GR, IE, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN, TD, TG, TR. (English). CODEN: PIXXD2. APPLICATION: WO 2001-US45242 20011129. PRIORITY: US 2000-250502P 20001201.

GI



I



II

AB The title compds. [I; Ar1 = (un)substituted (hetero)aryl; Ar2 = (un)substituted (hetero)aryl, aralkyl; or Ar1 and Ar2 together form (un)substituted fluorene, fluorenone with the proviso that Ar3 must be arylene; Ar3 = (un)substituted (hetero)arylene; X = O, S, N(CN); Y = a single bond, alkylene; R1 = thiazole, (hetero)aryl, etc.; R2 = H, alkyl], useful for the treatment of metabolic and eating disorders, such as hyperphagia, and for the treatment of diabetes, were prepared E.g., a multi-step synthesis of the urea II, starting with 4-bromoaniline and N-Boc-piperidone, was given. For compds. I, a range MCH receptor binding activity (Ki values) of from about 0.5 nM to about 100 nM was observed

IT 443936-25-6P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of substituted ureas as MCH antagonists useful in the treatment of obesity)

RN 443936-25-6 CAPLUS
CN Urea, N-(3'-cyano[1,1'-biphenyl]-4-yl)-N-(1-cyclopentyl-4-piperidinyl)-N'-[(2,5-dichlorophenyl)methyl]- (CA INDEX NAME)







RN 439918-03-3 CAPLUS
CN Benzamide, 4-[(1-cyclopentyl-4-piperidinyl)methyl]-N-[(1S)-1-(1-naphthalenyl)ethyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 439918-07-7 CAPLUS
CN Benzamide, 4-[(1-cyclopentyl-4-piperidinyl)methyl]-N-[(1S)-1-phenylethyl]- (CA INDEX NAME)

Absolute stereochemistry.



L6 ANSWER 15 OF 23 CAPLUS COPYRIGHT 2008 ACS on STN
2002:465965 Document No. 137:47128 Preparation of of ureido- and carbamoyloxy-substituted amides as inhibitors of factor Xa for the treatment of clotting disorders and tumors. Dorsch, Dieter; Maderski, Werner; Tsaklakidis, Christos; Cezanne, Bertram; Gleitz, Johannes; Barnes, Christopher (Merck Patent G.m.b.H., Germany). PCT Int. Appl. WO 2002045693 A1 20020620, 92 pp. DESIGNATED STATES: W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM; RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, CY, DE, DK, ES, FI, FR, GA, GB, GR, IE, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN, TD, TG, TR. (German). CODEN: PIXXD2. APPLICATION: WO 2001-EP13545 20011121. PRIORITY: DE 2000-10061008 20001216.

AB DNHCOXCHR1CONH(CH2)nEW [D = (substituted) Ph, pyridyl; R1 = H, Ar, Het, cycloalkyl, (substituted) A; R2 = H, A; E = (substituted) phenylene, piperidin-1,4-diyl; W = Ar, Het, N(R2)2, RZ, cycloalkyl; X = NH, O; A = (fluoro-substituted) (O-, S-, or CH:CH-interrupted) alkyl; Ar = (substituted) Ph; Het = (aromatic) (substituted) heterocyclyl; n = 0, 1],





L8 ANSWER 14 OF 23 CAPLUS COPYRIGHT 2008 ACS on STN
2002:504759 Document No. 137:78860 Preparation of benzylpiperidines as m2 muscarinic antagonists. McKittrick, Brian A.; Guo, Guihua; Zhu, Zhaoning; Ye, Yuanzan (Schering Corporation, USA). PCT Int. Appl. WO 2002051809 A2 20020704, 26 pp. DESIGNATED STATES: W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, HR, HU, ID, IL, IN, IS, JP, KG, KR, KZ, LC, LK, LR, LT, LU, LV, MA, MD, MG, MK, MN, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UZ, VN, YU, ZA, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM; RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, CY, DE, DK, ES, FI, FR, GA, GB, GR, IE, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN, TD, TG, TR. (English). CODEN: PIXXD2. APPLICATION: WO 2001-US49063 20011217. PRIORITY: US 2000-2000/PV257853 20001222.

GI



I



II

AB Title compds. [I; R1 = (substituted) cycloalkyl, cycloalkylalkyl, aryl, aralkyl, heteroaryl; R2 = H, alkyl, (substituted) cycloalkyl, cycloalkylalkyl, heterocycloalkyl, bridged cycloalkyl, bridged heterocycloalkyl; R3 = alkyl, CH2OH; R4 = H, alkyl], were prepared Thus, p-fluoroacetophenone, (S)-3,3-diphenyl-1-methyltetrahydro-2H-pyrrolo[1,2-c]oxaborole, and BH3.Me2S were stirred in THF/PhMe at 0° to give (R)-p-fluoro-α-methylbenzyl alc. This was stirred with diphenylphosphoryl azide and DBU in PhMe at -15° to give the azide, which was hydrogenated in MeOH containing HCl over Pd/C to give (S)-p-fluoro-α-methylbenzylamine. The latter was stirred 2 h with 4-(N-BOC-piperidinylmethyl)benzoic acid, 4-dimethylaminopyridine, and EDCI hydrochloride in CH2Cl2 to give N-[1-(S)-p-fluorophenethyl]-4-(4'-piperidinylmethyl)benzamide. Treatment of this with cyclohexanone and Na(AcO)3BH in dichloroethane gave title compound (II). I showed m2 muscarinic antagonistic activity in the range 1-500 nM.

IT 439918-01-1P 439918-03-3P 439918-04-4P
439918-05-5P 439918-06-6P 439918-07-7P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of benzylpiperidines as m2 muscarinic antagonists)

RN 439918-01-1 CAPLUS
CN Benzamide, 4-[(1-cyclopentyl-4-piperidinyl)methyl]-N-[(1S)-1-(4-





were prepared Thus, Z-D-Phe-OH, 2'-methylsulfonylbiphenyl-4-ylamine, N-(3-dimethylaminopropyl)-N'-ethylcarbodiimide hydrochloride, 1-hydroxybenzotriazole, and 4-methylmorpholine were stirred 40 h in DMF to give benzyl [(R)-1-(2'-methylsulfonylbiphenyl-4-ylcarbamoyl)-2-phenylethyl]carbamate. This was hydrogenolyzed in MeOH over Pd/C and the product was stirred with 4-chlorophenyl isocyanate in CH2Cl2 to give (R)-2-[3-(4-chlorophenyl)ureido]-N-(2'-methylsulfonylbiphen-4-yl)-3-phenylpropionamide. The latter inhibited factor Xa with IC50 = 8.6 + 10-8 M.

IT 438054-75-2P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(claimed compound; preparation of ureido- and carbamoyloxy-substituted amides as inhibitors of factor Xa for the treatment of clotting disorders such as strokes and cancer)

RN 438054-75-2 CAPLUS
CN Benzeneacetamide, α-[[[[4-chlorophenyl]amino]carbonyl]amino]-N-(1-cyclopentyl-4-piperidinyl)-, (αR)- (CA INDEX NAME)

Absolute stereochemistry.



L8 ANSWER 16 OF 23 CAPLUS COPYRIGHT 2008 ACS on STN
2002:142517 Document No. 136:200102 Preparation of N-cyclopentylpiperidines as modulators of chemokine receptor activity. Yang, Lihu; Butora, Gabor; Parsons, William H.; Pasternak, Alexander (Merck & Co., Inc., USA). PCT Int. Appl. WO 2002012924 A1 20020221, 274 pp. DESIGNATED STATES: W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM; RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, CY, DE, DK, ES, FI, FR, GA, GB, GR, IE, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN, TD, TG, TR. (English). CODEN: PIXXD2. APPLICATION: WO 2001-US25335 20010813. PRIORITY: US 2000-225923P 20000817.

GI





methylphenyl)ethyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 439918-04-4 CAPLUS
CN Benzamide, 4-[(1-cyclopentyl-4-piperidinyl)methyl]-N-[(1R)-2-hydroxy-1-phenylethyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 439918-05-5 CAPLUS
CN Benzamide, 4-[(1-cyclopentyl-4-piperidinyl)methyl]-N-[1-(4-fluorophenyl)ethyl]- (CA INDEX NAME)









I



II

AB The title compds. I (R1 = H, (un)substituted C0-6alkyl-Y-C1-6alkyl and C0-6alkyl-Y-C0-6alkyl-C3-7cycloalkyl-C0-6alkyl wherein Y = bond, O, S, SO, SO2 and alkylamine; R2 = (un)substituted C0-6alkyl-Ph and C0-6alkyl-heterocycle; R3 = (un)substituted C0-6alkyl-phenyl; R4 = H, OH, alkyl, alkylhydroxy, CN, etc. or R3 and R4 may be joined to form a ring selected from 1H-indene, 2,3-dihydro-1H-indene, 1,3-dihydrobenzofuran, 1,3-dihydroisobenzofuran, 2,3-dihydrobenzothiofuran, and 1,3-dihydroisobenzothiofuran or R3 and R5 or R4 and R6 may be joined to form a (un)substituted Ph ring; R5 and R6 may also be independently selected from H, OH, alkyl, halo, etc.; X = NR7, O, CONR7, CH2O, NR7CO, CO2, OCO, CH2(NR7)CO, N(COR7) and CH2N(COR7) where R7 = H, (un)substituted -alkyl, -benzyl, -Ph, and -C1-6alkyl-C3-6cycloalkyl) are prepared and disclosed as modulators of chemokine receptor activity. Thus, II was prepared by ozonolysis of Et 3-methylenecyclopentane carboxylate, substitution with trans-3-methyl-4-(1,1-spiroindenyl)piperidine (preparation given), hydrolysis of Intermediate Et spiropiperidinylmethylcyclpentane carboxylate and subsequent amidation by 3-trifluoromethyl-5-fluorobenzylamine. In particular, these compds. are useful as modulators of the chemokine receptor CCR-2 (no data). As chemokine receptor modulators, these compds. may be useful as anti-inflammatory and antirheumatic agents.

IT 400771-03-1P 400771-11-1P 400771-12-2P
400771-18-8P 400771-19-9P 400771-28-0P
400771-29-1P 400771-36-0P 400771-38-2P
400771-40-6P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(intermediate; preparation of chemokine receptor modulators N-cyclopentylpiperidines useful as anti-inflammatory and antirheumatic agents)

RN 400771-03-1 CAPLUS
CN Cyclopropanecarboxylic acid, 2-[3-[4-(4-fluorophenyl)-1-piperidinyl]-1-[[[[3-fluoro-5-(trifluoromethyl)phenyl]methyl]amino]carbonyl]cyclopentyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)



RN 400771-11-1 CAPLUS
CN Cyclopentanecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-1-[(1R,2R)-2-cyanocyclopropyl]-3-[4-(4-fluorophenyl)-1-piperidinyl]-, rel- (CA INDEX NAME)

Relative stereochemistry.



RN 400771-12-2 CAPLUS
CN Cyclopentanecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-1-[(1R,2S)-2-cyanocyclopropyl]-3-[4-(4-fluorophenyl)-1-piperidinyl]-, rel- (CA INDEX NAME)

Relative stereochemistry.



RN 400771-18-8 CAPLUS
CN Cyclopentanecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-1-cyano-3-[4-(4-fluorophenyl)-1-piperidinyl]-, (1R,3S)-rel- (CA INDEX NAME)

Relative stereochemistry.





RN 400771-38-2 CAPLUS
CN Cyclopentanecarboxylic acid, 1-[[[[3,5-bis(trifluoromethyl)phenyl]methyl]amino]carbonyl]-3-[4-(4-fluorophenyl)-1-piperidinyl]-, (1R,3R)-rel- (CA INDEX NAME)

Relative stereochemistry.



RN 400771-40-6 CAPLUS
CN Cyclopentanecarbonyl chloride, 1-[[[[3,5-bis(trifluoromethyl)phenyl]methyl]amino]carbonyl]-3-[4-(4-fluorophenyl)-1-piperidinyl]-, monohydrochloride, (1R,3R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



● HCl

IT 400765-28-8P 400765-32-4P 400766-20-3P
400766-21-4P 400766-24-7P 400766-32-7P
400766-37-2P 400766-43-0P 400766-45-2P
400766-46-3P 400766-55-4P 400767-91-1P
400769-25-7P 400769-26-8P
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)







RN 400771-19-9 CAPLUS
CN Cyclopentanecarboxamide, 1-cyano-3-[4-(4-fluorophenyl)-1-piperidinyl]-N-[[3-fluoro-5-(trifluoromethyl)phenyl]methyl]-, (1R,3S)-rel- (CA INDEX NAME)

Relative stereochemistry.



RN 400771-28-0 CAPLUS
CN Cyclopentanecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-1-[2-[[(1,1-dimethylethyl)diphenylsilyl]oxy]ethyl]-3-[4-(4-fluorophenyl)-1-piperidinyl]-, (1R,3S)-rel- (CA INDEX NAME)

Relative stereochemistry.



(target compound; preparation of chemokine receptor modulators N-cyclopentylpiperidines useful as anti-inflammatory and antirheumatic agents)

RN 400765-28-8 CAPLUS
CN Cyclopentanecarboxamide, 3-[4-(4-fluorophenyl)-1-piperidinyl]-N-[[3-fluoro-5-(trifluoromethyl)phenyl]methyl]-1-(1-hydroxy-1-methylethyl)-, (1S,3R)-(CA INDEX NAME)

Absolute stereochemistry.



RN 400765-32-4 CAPLUS
CN Cyclopentanecarboxamide, 3-[4-(4-fluorophenyl)-1-piperidinyl]-N-[[3-fluoro-5-(trifluoromethyl)phenyl]methyl]-1-(2-methyl-2-propenyl)-, (1R,3R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 400766-20-3 CAPLUS
CN Cyclopentanecarboxamide, 3-[(1R,4S)-4-(4-fluorophenyl)-3-hydroxy-1-piperidinyl]-N-[[3-fluoro-5-(trifluoromethyl)phenyl]methyl]-1-(1-methylethyl)-, rel- (CA INDEX NAME)

Relative stereochemistry.







RN 400771-29-1 CAPLUS
CN Cyclopentanecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-3-[4-(4-fluorophenyl)-1-piperidinyl]-1-(2-hydroxyethyl)-, (1R,3S)-rel- (CA INDEX NAME)

Relative stereochemistry.



RN 400771-36-0 CAPLUS
CN Cyclopentanecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-3-[4-(4-fluorophenyl)-1-piperidinyl]-1-[[(methylsulfonyl)oxy]methyl]- (CA INDEX NAME)









RN 400766-21-4 CAPLUS
CN Cyclopentanecarboxamide, 3-(4-fluoro-4-phenyl-1-piperidinyl)-N-[[3-fluoro-5-(trifluoromethyl)phenyl]methyl]-1-(1-methylethyl)- (CA INDEX NAME)



RN 400766-24-7 CAPLUS
CN Cyclopropanecarboxylic acid, 2-[3-[4-(4-fluorophenyl)-1-piperidinyl]-1-[[[[3-fluoro-5-(trifluoromethyl)phenyl]methyl]amino]carbonyl]cyclopentyl]-(CA INDEX NAME)



RN 400766-32-7 CAPLUS
CN Cyclopentanecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-1-(2-cyanocyclopropyl)-3-[4-(4-fluorophenyl)-1-piperidinyl]- (CA INDEX NAME)



RN 400766-37-2 CAPLUS
CN Cyclopentanecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-3-[4-(4-fluorophenyl)-1-piperidinyl]-1-[2-[(hydroxyamino)iminomethyl]cyclopropyl]- (CA INDEX NAME)



RN 400766-41-0 CAPLUS
CN Cyclopentanecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-3-[4-(4-fluorophenyl)-1-piperidinyl]-1-(2-hydroxyethyl)- (CA INDEX NAME)



RN 400766-45-2 CAPLUS
CN Cyclopentanecarboxylic acid, 1-[[[[3,5-bis(trifluoromethyl)phenyl]methyl]amino]carbonyl]-3-[4-(4-fluorophenyl)-1-piperidinyl]-, ethyl ester, (1R,3R)-rel- (CA INDEX NAME)

Relative stereochemistry.



RN 400766-46-3 CAPLUS
CN Cyclopentanecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-3-[4-(4-fluorophenyl)-1-piperidinyl]-1-(hydroxymethyl)- (CA INDEX NAME)





400766-33-4P 400766-40-7P 400766-41-8P
400766-42-9P 400766-44-1P 400766-48-5P
400766-49-6P 400766-51-0P 400766-53-2P
400766-57-6P 400766-59-8P 400766-61-2P
400766-63-4P 400766-65-6P 400766-67-8P
400766-69-0P 400767-83-1P 400767-85-3P
400767-86-4P 400767-87-5P 400767-88-6P
400767-89-7P 400767-90-0P 400767-92-2P
400767-93-3P 400767-95-5P 400767-96-6P
400767-97-7P 400767-98-8P 400767-99-9P
400768-00-5P 400768-01-6P 400768-02-7P
400768-10-7P 400768-11-8P 400768-12-9P
400768-13-0P 400768-14-1P 400768-15-2P
400768-16-3P 400768-17-4P 400768-18-5P
400768-33-4P 400768-34-5P 400768-53-6P
400769-54-9P 400769-55-0P 400768-56-1P
400769-63-0P 400769-64-1P 400768-65-2P
400768-66-3P 400768-67-4P 400768-68-5P
400768-69-6P 400768-70-9P 400768-71-0P
400768-72-1P 400768-73-2P 400768-74-3P
400768-75-4P 400768-76-5P 400768-78-7P
400768-83-4P 400768-84-5P 400768-85-6P
400768-86-7P 400768-87-8P 400768-88-9P
400769-89-0P 400768-90-3P 400768-96-9P
400769-97-0P 400769-02-0P 400769-03-1P
400769-04-2P 400769-05-3P 400769-06-4P
400769-07-5P 400769-09-6P 400769-15-5P
400769-16-6P 400769-23-5P 400769-24-6P
400769-27-9P 400769-28-0P 400769-29-1P
400769-30-4P 400769-31-5P 400769-32-6P
400769-33-7P 400769-34-8P 400769-35-9P
400769-36-0P 400769-37-1P 400769-38-2P
400769-39-3P 400769-40-6P 400769-41-7P
400769-42-8P 400769-43-9P 400769-44-0P
400769-45-1P 400769-46-2P
RL: PAC (Pharmacological activity); SFN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(target compound; preparation of chemokine receptor modulators N-cyclopentylpiperidines useful as anti-inflammatory and antirheumatic agents)

RN 400764-51-4 CAPLUS
CN Cyclopentanecarboxamide, N-[(2-ethoxyphenyl)methyl]-3-[4-(4-fluorophenyl)-1-piperidinyl]-1-(1-methylethyl)- (CA INDEX NAME)



RN 400764-53-6 CAPLUS
CN Cyclopentanecarboxamide, N-[[2-(difluoromethoxy)phenyl]methyl]-3-[4-(4-fluorophenyl)-1-piperidinyl]-1-(1-methylethyl)- (CA INDEX NAME)







RN 400766-55-4 CAPLUS
CN Cyclopentanecarboxamide, 1-(aminomethyl)-N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-3-[4-(4-fluorophenyl)-1-piperidinyl]-1-(CA INDEX NAME)



RN 400767-91-1 CAPLUS
CN Cyclopentanecarboxamide, 3-[4-(4-fluorophenyl)-1-piperidinyl]-1-(1-methylethyl)-N-[[3-[5-(trifluoromethyl)-1H-tetrazol-1-yl]phenyl]methyl]-, (1R,3S)-rel- (CA INDEX NAME)

Relative stereochemistry.



RN 400769-25-7 CAPLUS
CN Cyclopentanecarboxamide, 1-[2-(aminocarbonyl)cyclopropyl]-3-[4-(4-fluorophenyl)-1-piperidinyl]-N-[[3-fluoro-5-(trifluoromethyl)phenyl]methyl]- (CA INDEX NAME)







RN 400766-55-8 CAPLUS
CN Cyclopentanecarboxamide, N-[(5-chloro-2-methoxyphenyl)methyl]-3-[4-(4-fluorophenyl)-1-piperidinyl]-1-(1-methylethyl)- (CA INDEX NAME)



RN 400764-57-0 CAPLUS
CN Cyclopentanecarboxamide, 3-[4-(4-fluorophenyl)-1-piperidinyl]-N-[(2-methoxy-5-(trifluoromethyl)phenyl]methyl]-1-(1-methylethyl)- (CA INDEX NAME)



RN 400764-59-2 CAPLUS
CN Cyclopentanecarboxamide, N-[[2-chloro-5-(trifluoromethyl)phenyl]methyl]-3-[4-(4-fluorophenyl)-1-piperidinyl]-1-(1-methylethyl)- (CA INDEX NAME)









RN 400769-26-8 CAPLUS
CN Cyclopentanecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-1-[(1R,2R)-2-cyanocyclopropyl]-3-[4-(4-fluorophenyl)-1-piperidinyl]-, (1S,3R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



IT 400764-51-4P 400764-53-6P 400764-55-8P
400764-57-0P 400764-59-2P 400764-60-5P
400764-62-7P 400764-66-1P 400764-68-3P
400764-70-7P 400764-71-8P 400764-73-0P
400764-74-1P 400764-75-2P 400764-76-3P
400764-78-5P 400764-80-9P 400764-81-0P
400764-83-2P 400764-85-4P 400764-87-6P
400765-03-9P 400765-05-1P 400765-07-3P
400765-09-5P 400765-10-8P 400765-12-0P
400765-14-2P 400765-16-4P 400765-18-6P
400765-30-2P 400765-34-6P 400765-36-8P
400765-38-0P 400765-39-1P 400765-41-5P
400765-60-8P 400765-65-3P 400765-67-5P
400765-68-6P 400765-70-0P 400765-72-2P
400765-73-3P 400765-76-6P 400765-78-8P
400765-79-9P 400765-80-2P 400765-82-4P
400765-85-7P 400765-87-9P 400765-88-0P
400765-90-4P 400765-91-5P 400765-92-6P
400765-94-8P 400765-95-9P 400765-96-0P
400765-97-1P 400765-98-2P 400765-99-3P
400766-00-9P 400766-01-0P 400766-02-1P
400766-04-3P 400766-05-4P 400766-06-5P
400766-08-7P 400766-12-3P 400766-13-4P
400766-22-5P 400766-25-8P 400766-27-0P
400766-29-1P 400766-29-2P 400766-30-5P
400766-31-6P 400766-33-8P 400766-34-9P
400766-35-0P 400766-36-1P 400766-38-3P





RN 400764-60-5 CAPLUS
CN Cyclopentanecarboxamide, 3-[4-(4-fluorophenyl)-1-piperidinyl]-N-[[3-(1-methylethoxy)phenyl]methyl]-1-(1-methylethyl)- (CA INDEX NAME)



RN 400764-62-7 CAPLUS
CN Cyclopentanecarboxamide, 3-[4-(4-fluorophenyl)-1-piperidinyl]-1-(1-methylethyl)-N-[[3-[(methylsulfonyl)amino]phenyl]methyl]- (CA INDEX NAME)



RN 400764-66-1 CAPLUS
CN Cyclopentanecarboxamide, 3-[4-(4-fluorophenyl)-1-piperidinyl]-1-(1-methylethyl)-N-[[3-[(trifluoromethyl)thio]phenyl]methyl]- (CA INDEX NAME)



RN 400764-68-3 CAPLUS
CN Cyclopentanecarboxamide, 3-[4-(4-fluorophenyl)-1-piperidinyl]-1-(1-methylethyl)-N-[[3-[5-(trifluoromethyl)-1H-tetrazol-1-yl]phenyl]methyl]- (CA INDEX NAME)



RN 400764-70-7 CAPLUS
CN Cyclopentanecarboxamide, N-[(3,4-dichlorophenyl)methyl]-3-[4-(4-fluorophenyl)-1-piperidinyl]-1-(1-methylethyl)- (CA INDEX NAME)



RN 400764-71-8 CAPLUS
CN Cyclopentanecarboxamide, N-[(3,4-difluorophenyl)methyl]-3-[4-(4-fluorophenyl)-1-piperidinyl]-1-(1-methylethyl)- (CA INDEX NAME)



RN 400764-73-0 CAPLUS
CN Cyclopentanecarboxamide, 3-[4-(4-fluorophenyl)-1-piperidinyl]-N-[(2-methoxyphenyl)methyl]-1-(1-methylethyl)- (CA INDEX NAME)



RN 400764-74-1 CAPLUS
CN Cyclopentanecarboxamide, 3-[4-(4-fluorophenyl)-1-piperidinyl]-1-(1-methylethyl)-N-(phenylmethyl)- (CA INDEX NAME)



RN 400764-75-2 CAPLUS





CN Cyclopentanecarboxamide, 3-[4-(4-fluorophenyl)-1-piperidinyl]-1-(1-methylethyl)-N-[(1S)-1-phenylethyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 400764-76-3 CAPLUS
CN Cyclopentanecarboxamide, 3-[4-(4-fluorophenyl)-1-piperidinyl]-1-(1-methylethyl)-N-(1-methyl-1-phenylethyl)- (CA INDEX NAME)



RN 400764-78-5 CAPLUS
CN Benzeneacetic acid, α-[[[3-[4-(4-fluorophenyl)-1-piperidinyl]-1-(1-methylethyl)cyclopentyl]carbonyl]amino]-3-(trifluoromethyl)-, methyl ester (CA INDEX NAME)



RN 400764-80-9 CAPLUS
CN Cyclopentanecarboxamide, 1-(1-methylethyl)-3-(4-phenyl-1-piperidinyl)-N-[(3-(trifluoromethyl)phenyl]methyl]- (CA INDEX NAME)







RN 400764-81-0 CAPLUS
CN Cyclopentanecarboxamide, N-[(3-fluoro-5-(trifluoromethyl)phenyl]methyl]-1-(1-methylethyl)-3-(4-phenyl-1-piperidinyl)- (CA INDEX NAME)



RN 400764-83-2 CAPLUS
CN Cyclopentanecarboxamide, 1-(1-methylethyl)-3-(4-phenyl-1-piperidinyl)-N-[(3-(trifluoromethoxy)phenyl]methyl]- (CA INDEX NAME)



RN 400764-85-4 CAPLUS
CN Cyclopentanecarboxamide, N-[(3-(difluoromethoxy)phenyl]methyl]-1-(1-methylethyl)-3-(4-phenyl-1-piperidinyl)- (CA INDEX NAME)



RN 400764-87-6 CAPLUS
CN Cyclopentanecarboxamide, N-[(3-chlorophenyl]methyl]-1-(1-methylethyl]-3-(4-phenyl-1-piperidinyl)- (CA INDEX NAME)







RN 400765-03-9 CAPLUS
CN Cyclopentanecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-1-cyclopropyl-3-(4-phenyl-1-piperidinyl)-. (CA INDEX NAME)



RN 400765-05-1 CAPLUS
CN Cyclopentanecarboxamide, 1-cyclopropyl-N-[(3-fluoro-5-(trifluoromethyl)phenyl]methyl]-3-(4-phenyl-1-piperidinyl)- (CA INDEX NAME)



RN 400765-07-3 CAPLUS
CN Cyclopentanecarboxamide, 1-cyclopropyl-3-(4-phenyl-1-piperidinyl)-N-[(3-(trifluoromethyl)phenyl]methyl]- (CA INDEX NAME)



RN 400765-09-5 CAPLUS
CN Cyclopentanecarboxamide, N-[(3,5-bis(trifluoromethyl)phenyl]methyl]-1-cyclopropyl-3-[4-(4-fluorophenyl)-1-piperidinyl]- (CA INDEX NAME)







RN 400765-10-8 CAPLUS
CN Cyclopentanecarboxamide, 1-cyclopropyl-3-[4-(4-fluorophenyl)-1-piperidinyl]-N-[[3-fluoro-5-(trifluoromethyl)phenyl]methyl]- (CA INDEX NAME)



RN 400765-12-0 CAPLUS
CN Cyclopentanecarboxamide, 1-cyclopropyl-3-[4-(4-fluorophenyl)-1-piperidinyl]-N-[[3-(trifluoromethyl)phenyl]methyl]- (CA INDEX NAME)



RN 400765-14-2 CAPLUS
CN Cyclopentanecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-1-cyclopropyl-3-(1-piperidinyl)- (CA INDEX NAME)



RN 400765-16-4 CAPLUS
CN Cyclopentanecarboxamide, 1-cyclopropyl-N-[[3-fluoro-5-(trifluoromethyl)phenyl]methyl]-3-(1-piperidinyl)- (CA INDEX NAME)







RN 400765-18-6 CAPLUS
CN Cyclopentanecarboxamide, 1-cyclopropyl-3-(1-piperidinyl)-N-[(3-(trifluoromethyl)phenyl]methyl]- (CA INDEX NAME)



RN 400765-30-2 CAPLUS
CN Cyclopentanecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-3-[4-(4-fluorophenyl)-1-piperidinyl]-1-(1-hydroxy-1-methylethyl)-, (1S,3R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 400765-34-6 CAPLUS
CN Cyclopentanecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-1-(1-hydroxy-1-methylethyl)-3-(4-phenyl-1-piperidinyl)-, (1R,3S)-rel- (CA INDEX NAME)

Relative stereochemistry.



RN 400765-36-8 CAPLUS
CN Cyclopentanecarboxamide, N-[[3-fluoro-5-(trifluoromethyl)phenyl]methyl]-1-(1-hydroxy-1-methylethyl)-3-(4-phenyl-1-piperidinyl)-, (1R,3S)-rel- (CA INDEX NAME)

Relative stereochemistry.



RN 400765-38-0 CAPLUS
CN Cyclopentanecarboxamide, 1-(1-hydroxy-1-methylethyl)-3-(4-phenyl-1-piperidinyl)-N-[[3-(trifluoromethyl)phenyl]methyl]-, (1R,3S)-rel- (CA INDEX NAME)

Relative stereochemistry.



RN 400765-39-1 CAPLUS
CN Cyclopentanecarboxamide, 1-(1-hydroxy-1-methylethyl)-3-(4-phenyl-1-piperidinyl)-N-[[3-(trifluoromethoxy)phenyl]methyl]-, (1R,3S)-rel- (CA INDEX NAME)

Relative stereochemistry.





5-(trifluoromethyl)phenyl]methyl]-1-(2-methylpropyl)- (CA INDEX NAME)



RN 400765-76-6 CAPLUS
CN Cyclopentanecarboxamide, N-[[3-fluoro-5-(trifluoromethyl)phenyl]methyl]-1-(2-methylpropyl)-3-(1-piperidinyl)- (CA INDEX NAME)



RN 400765-78-8 CAPLUS
CN Cyclopentanecarboxamide, N-[[3-fluoro-5-(trifluoromethyl)phenyl]methyl]-3-(4-hydroxy-4-phenyl-1-piperidinyl)-1-(2-methylpropyl)- (CA INDEX NAME)



RN 400765-79-9 CAPLUS
CN Cyclopentanecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-1-(1-methylethyl)-3-(4-phenyl-1-piperidinyl)- (CA INDEX NAME)



RN 400765-80-2 CAPLUS
CN Cyclopentanecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-3-[4-(4-fluorophenyl)-1-piperidinyl]-1-(1-methylethyl)- (CA INDEX NAME)







RN 400765-41-5 CAPLUS
CN Cyclopentanecarboxamide, N-[[3-(difluoromethoxy)phenyl]methyl]-1-(1-hydroxy-1-methylethyl)-3-(4-phenyl-1-piperidinyl)-, (1R,3S)-rel- (CA INDEX NAME)

Relative stereochemistry.



RN 400765-60-8 CAPLUS
CN Cyclopentanecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-3-(4-phenyl-1-piperidinyl)- (CA INDEX NAME)



RN 400765-65-3 CAPLUS
CN Cyclopentanecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-1-(2-methylpropyl)-3-(4-phenyl-1-piperidinyl)- (CA INDEX NAME)









RN 400765-82-4 CAPLUS
CN Cyclopentanecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-1-(1-methylethyl)-3-(1-piperidinyl)- (CA INDEX NAME)



RN 400765-85-7 CAPLUS
CN Cyclopentanecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-3-(4-hydroxy-4-phenyl-1-piperidinyl)-1-(1-methylethyl)- (CA INDEX NAME)



RN 400765-87-9 CAPLUS
CN Cyclopentanecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-1-(1-methylethyl)-3-[(3R,4S)-3-methyl-4-phenyl-1-piperidinyl]-, rel- (CA INDEX NAME)

Relative stereochemistry.







RN 400765-67-5 CAPLUS
CN Cyclopentanecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-3-[4-(4-fluorophenyl)-1-piperidinyl]-1-(2-methylpropyl)- (CA INDEX NAME)



RN 400765-68-6 CAPLUS
CN Cyclopentanecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-1-(2-methylpropyl)-3-(1-piperidinyl)- (CA INDEX NAME)



RN 400765-70-0 CAPLUS
CN Cyclopentanecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-3-(4-hydroxy-4-phenyl-1-piperidinyl)-1-(2-methylpropyl)- (CA INDEX NAME)



RN 400765-72-2 CAPLUS
CN Cyclopentanecarboxamide, N-[[3-fluoro-5-(trifluoromethyl)phenyl]methyl]-1-(2-methylpropyl)-3-(4-phenyl-1-piperidinyl)- (CA INDEX NAME)



RN 400765-73-3 CAPLUS
CN Cyclopentanecarboxamide, 3-[4-(4-fluorophenyl)-1-piperidinyl]-N-[[3-fluoro-





RN 400765-88-0 CAPLUS
CN Benzoic acid, 2-[1-[3-[[[[3,5-bis(trifluoromethyl)phenyl]methyl]amino]carbonyl]-3-(1-methylethyl)cyclopentyl]-4-piperidinyl]-, methyl ester (CA INDEX NAME)



RN 400765-90-4 CAPLUS
CN Cyclopentanecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-1-(1-methylethyl)-3-(3-methyl-1-piperidinyl)- (CA INDEX NAME)



RN 400765-91-5 CAPLUS
CN Cyclopentanecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-3-(3,5-dimethyl-1-piperidinyl)-1-(1-methylethyl)- (CA INDEX NAME)



RN 400765-92-6 CAPLUS
CN Cyclopentanecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-1-(1-methylethyl)-3-(4-methyl-1-piperidinyl)- (CA INDEX NAME)



RN 400765-94-8 CAPLUS
CN Cyclopentanecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-1-(1-methylethyl)-3-[4-(trifluoromethyl)-1-piperidinyl]- (CA INDEX NAME)



RN 400765-95-9 CAPLUS
CN 3-Piperidinecarboxylic acid, 1-[3-[[[3,5-bis(trifluoromethyl)phenyl]methyl]amino]carbonyl]-3-(1-methylethyl)cyclopentyl]-, ethyl ester (CA INDEX NAME)



RN 400765-96-0 CAPLUS
CN Cyclopentanecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-3-(3-hydroxy-1-piperidinyl)-1-(1-methylethyl)- (CA INDEX NAME)



RN 400765-97-1 CAPLUS
CN Cyclopentanecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-3-[3-(hydroxymethyl)-1-piperidinyl]-1-(1-methylethyl)- (CA INDEX NAME)









RN 400766-06-5 CAPLUS
CN Cyclopentanecarboxamide, 1-(1-methylethyl)-3-(1-piperidinyl)-N-[[3-(trifluoromethyl)phenyl]methyl]- (CA INDEX NAME)



RN 400766-08-7 CAPLUS
CN Cyclopentanecarboxamide, 3-[4-(4-fluorophenyl)-1-piperidinyl]-1-(1-methylethyl)-N-[[3-(trifluoromethyl)phenyl]methyl]- (CA INDEX NAME)



RN 400766-12-3 CAPLUS
CN Cyclopentanecarboxamide, 1-[1-(acetylamino)-1-methylethyl]-3-[4-(4-fluorophenyl)-1-piperidinyl]-N-[[3-fluoro-5-(trifluoromethyl)phenyl]methyl]-, (1S,3R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 400766-13-4 CAPLUS





RN 400765-98-2 CAPLUS
CN 4-Piperidinecarboxylic acid, 1-[3-[[[[3,5-bis(trifluoromethyl)phenyl]methyl]amino]carbonyl]-3-(1-methylethyl)cyclopentyl]-, ethyl ester (CA INDEX NAME)



RN 400765-99-3 CAPLUS
CN Cyclopentanecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-3-(4-cyano-1-piperidinyl)-1-(1-methylethyl)- (CA INDEX NAME)



RN 400766-00-9 CAPLUS
CN Cyclopentanecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-3-(4-hydroxy-1-piperidinyl)-1-(1-methylethyl)- (CA INDEX NAME)



RN 400766-01-0 CAPLUS
CN 4-Piperidinecarboxylic acid, 1-[3-[[[[3,5-bis(trifluoromethyl)phenyl]methyl]amino]carbonyl]-3-(1-methylethyl)cyclopentyl]-4-phenyl-, ethyl ester (CA INDEX NAME)





CN Cyclopentanecarboxamide, 1-[2-(acetylamino)-2-methylpropyl]-3-[4-(4-fluorophenyl)-1-piperidinyl]-N-[[3-fluoro-5-(trifluoromethyl)phenyl]methyl]-, (1S,3R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 400766-22-5 CAPLUS
CN Cyclopentanecarboxamide, 3-[(3R,4R)-4-(4-fluorophenyl)-3-hydroxy-1-piperidinyl]-N-[[3-fluoro-5-(trifluoromethyl)phenyl]methyl]-1-(1-methylethyl)-, rel- (CA INDEX NAME)

Relative stereochemistry.



RN 400766-25-6 CAPLUS
CN Cyclopentanecarboxamide, 1-[2-[(ethylamino)carbonyl]cyclopropyl]-3-[4-(4-fluorophenyl)-1-piperidinyl]-N-[[3-fluoro-5-(trifluoromethyl)phenyl]methyl]- (CA INDEX NAME)







RN 400766-02-1 CAPLUS
CN Cyclopentanecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-3-[(3R,4S)-4-(4-fluorophenyl)-3-methyl-1-piperidinyl]-1-(1-methylethyl)-, rel- (CA INDEX NAME)

Relative stereochemistry.



RN 400766-04-3 CAPLUS
CN Cyclopentanecarboxamide, N-[[3-fluoro-5-(trifluoromethyl)phenyl]methyl]-1-(1-methylethyl)-3-(1-piperidinyl)- (CA INDEX NAME)



RN 400766-05-4 CAPLUS
CN Cyclopentanecarboxamide, 3-[4-(4-fluorophenyl)-1-piperidinyl]-N-[[3-fluoro-5-(trifluoromethyl)phenyl]methyl]-1-(1-methylethyl)- (CA INDEX NAME)







RN 400766-27-0 CAPLUS
CN Cyclopentanecarboxamide, 1-[2-[(dimethylamino)carbonyl]cyclopropyl]-3-[4-(4-fluorophenyl)-1-piperidinyl]-N-[[3-fluoro-5-(trifluoromethyl)phenyl]methyl]- (CA INDEX NAME)



RN 400766-28-1 CAPLUS
CN Cyclopentanecarboxamide, 3-[4-(4-fluorophenyl)-1-piperidinyl]-N-[[3-fluoro-5-(trifluoromethyl)phenyl]methyl]-1-[2-(1-pyrrolidinylcarbonyl)cyclopropyl]- (CA INDEX NAME)



RN 400766-29-2 CAPLUS
CN Cyclopentanecarboxamide, 3-[4-(4-fluorophenyl)-1-piperidinyl]-N-[[3-fluoro-5-(trifluoromethyl)phenyl]methyl]-1-[2-[[(1-methylethyl)amino]carbonyl]cyclopropyl]- (CA INDEX NAME)



RN 400766-30-5 CAPLUS
CN Cyclopropanecarboxylic acid, 2-[3-[4-(4-fluorophenyl)-1-piperidinyl]-1-[[[[3-fluoro-5-(trifluoromethyl)phenyl]methyl]amino]carbonyl]cyclopentyl]-, methyl ester (CA INDEX NAME)



RN 400766-31-6 CAPLUS
CN Cyclopentanecarboxamide, 3-[4-(4-fluorophenyl)-1-piperidinyl]-N-[[3-fluoro-5-(trifluoromethyl)phenyl]methyl]-1-[2-[[(methylsulfonyl)amino]carbonyl]cyclopropyl]- (CA INDEX NAME)



RN 400766-33-8 CAPLUS
CN Cyclopentanecarboxamide, 1-(2-cyanocyclopropyl)-3-[4-(4-fluorophenyl)-1-piperidinyl]-N-[[3-fluoro-5-(trifluoromethyl)phenyl]methyl]- (CA INDEX NAME)







RN 400766-34-9 CAPLUS
CN Cyclopentanecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-3-[4-[4-fluorophenyl]-1-piperidinyl]-1-[2-(1H-tetrazol-5-yl)cyclopropyl]- (9CI) (CA INDEX NAME)



RN 400766-35-0 CAPLUS
CN Cyclopentanecarboxamide, 3-[4-(4-fluorophenyl)-1-piperidinyl]-N-[[3-fluoro-5-(trifluoromethyl)phenyl]methyl]-1-[2-[5-methyl-1,3,4-oxadiazol-2-yl)cyclopropyl]- (CA INDEX NAME)



RN 400766-36-1 CAPLUS
CN Cyclopentanecarboxamide, 3-[4-(4-fluorophenyl)-1-piperidinyl]-N-[[3-fluoro-5-(trifluoromethyl)phenyl]methyl]-1-[2-(1H-1,2,4-triazol-3-yl)cyclopropyl]- (9CI) (CA INDEX NAME)







RN 400766-38-3 CAPLUS
CN Cyclopentanecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-1-[2-(2,5-dihydro-5-oxo-1,2,4-oxadiazol-3-yl)cyclopropyl]-3-[4-(4-fluorophenyl)-1-piperidinyl]- (CA INDEX NAME)



RN 400766-39-4 CAPLUS
CN Cyclopentanecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-3-[4-[4-fluorophenyl]-1-piperidinyl]-1-[2-(5-methyl-1,2,4-oxadiazol-3-yl)cyclopropyl]- (CA INDEX NAME)







RN 400766-40-7 CAPLUS
CN Cyclopentanecarboxamide, 3-[4-(4-fluorophenyl)-1-piperidinyl]-N-[[3-fluoro-5-(trifluoromethyl)phenyl]methyl]-1-[2-[3-methyl-1,2,4-oxadiazol-5-yl)cyclopropyl]- (CA INDEX NAME)



RN 400766-41-5 CAPLUS
CN 1,1-Cyclopentanedicarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-3-[4-(4-fluorophenyl)-1-piperidinyl]- (CA INDEX NAME)



RN 400766-42-9 CAPLUS
CN Cyclopentanecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-3-[4-(4-fluorophenyl)-1-piperidinyl]-1-[(hydroxyamino)iminomethyl]- (CA INDEX NAME)







RN 400766-44-1 CAPLUS
CN Cyclopentanecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-3-[4-(4-fluorophenyl)-1-piperidinyl]-1-(3-hydroxypropyl)- (CA INDEX NAME)



RN 400766-46-5 CAPLUS
CN Cyclopentanecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-3-[4-(4-fluorophenyl)-1-piperidinyl]-1-formyl- (CA INDEX NAME)



RN 400766-49-8 CAPLUS
CN Cyclopentanecarboxamide, 1-[(acetyloxy)methyl]-N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-3-[4-(4-fluorophenyl)-1-piperidinyl]- (CA INDEX NAME)



RN 400766-51-0 CAPLUS





CN Cyclopentanecarboxamide, 1-[2-(acetyloxy)ethyl]-N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-3-[4-(4-fluorophenyl)-1-piperidinyl]- (CA INDEX NAME)



RN 400766-53-2 CAPLUS
CN Cyclopentanecarboxamide, 1-(azidomethyl)-N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-3-[4-(4-fluorophenyl)-1-piperidinyl]- (CA INDEX NAME)



RN 400766-57-6 CAPLUS
CN Cyclopentanecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-3-[4-(4-fluorophenyl)-1-piperidinyl]-1-[[(methylsulfonyl)amino]methyl]- (CA INDEX NAME)



RN 400766-59-8 CAPLUS
CN Carbamic acid, [[1-[[[[3,5-bis(trifluoromethyl)phenyl]methyl]amino]carbonyl]-3-[4-(4-fluorophenyl)-1-piperidinyl]cyclopentyl]methyl]-, methyl ester (9CI) (CA INDEX NAME)



RN 400766-61-2 CAPLUS
CN Cyclopentanecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-1-[(dimethylamino)methyl]-3-[4-(4-fluorophenyl)-1-piperidinyl]- (CA INDEX NAME)



RN 400766-63-4 CAPLUS
CN Cyclopentanecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-3-[4-(4-fluorophenyl)-1-piperidinyl]-1-(4H-1,2,4-triazol-4-ylmethyl)- (CA INDEX NAME)







CN Cyclopentanecarboxamide, 3-[4-(4-fluorophenyl)-1-piperidinyl]-N-[[2-methoxy-5-(trifluoromethyl)phenyl]methyl]-1-(1-methylethyl)-, (1R,3S)-rel- (CA INDEX NAME)

Relative stereochemistry.



RN 400766-68-6 CAPLUS
CN Cyclopentanecarboxamide, N-[[2-chloro-5-(trifluoromethyl)phenyl]methyl]-3-[4-(4-fluorophenyl)-1-piperidinyl]-1-(1-methylethyl)-, (1R,3S)-rel- (CA INDEX NAME)

Relative stereochemistry.



RN 400767-53-7 CAPLUS
CN Cyclopentanecarboxamide, 3-[4-(4-fluorophenyl)-1-piperidinyl]-1-(1-methylethyl)-N-[[3-[(methylsulfonyl)amino]phenyl]methyl]-, (1R,3S)-rel- (CA INDEX NAME)

Relative stereochemistry.





RN 400766-65-6 CAPLUS
CN 1,1-Cyclopentanedicarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-3-[4-(4-fluorophenyl)-1-piperidinyl]-N'-(1-methylethyl)- (CA INDEX NAME)



RN 400766-67-8 CAPLUS
CN 1,1-Cyclopentanedicarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-3-[4-(4-fluorophenyl)-1-piperidinyl]-N'-methyl- (CA INDEX NAME)



RN 400766-69-0 CAPLUS
CN Cyclopentanecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-3-[4-(4-fluorophenyl)-1-piperidinyl]-1-(1-pyrrolidinylcarbonyl)- (CA INDEX NAME)



RN 400767-83-1 CAPLUS
CN Cyclopentanecarboxamide, N-[(2-ethoxyphenyl)methyl]-3-[4-(4-fluorophenyl)-1-piperidinyl]-1-(1-methylethyl)-, (1R,3S)-rel- (CA INDEX NAME)

Relative stereochemistry.







RN 400766-90-0 CAPLUS
CN Cyclopentanecarboxamide, 3-[4-(4-fluorophenyl)-1-piperidinyl]-1-(1-methylethyl)-N-[[3-[(trifluoromethyl)thio]phenyl]methyl]-, (1R,3S)-rel- (CA INDEX NAME)

Relative stereochemistry.



RN 400767-92-2 CAPLUS
CN Cyclopentanecarboxamide, 3-[4-(4-fluorophenyl)-1-piperidinyl]-1-(1-methylethyl)-N-[[3-[5-(trifluoromethyl)-1H-tetrazol-1-yl]phenyl]methyl]-, monohydrochloride, (1R,3S)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



● HCl







RN 400767-85-3 CAPLUS
CN Cyclopentanecarboxamide, N-[[2-(difluoromethoxy)phenyl]methyl]-3-[4-(4-fluorophenyl)-1-piperidinyl]-1-(1-methylethyl)-, (1R,3S)-rel- (CA INDEX NAME)

Relative stereochemistry.



RN 400767-86-4 CAPLUS
CN Cyclopentanecarboxamide, N-[(5-chloro-2-methoxyphenyl)methyl]-3-[4-(4-fluorophenyl)-1-piperidinyl]-1-(1-methylethyl)-, (1R,3S)-rel- (CA INDEX NAME)

Relative stereochemistry.



RN 400767-87-5 CAPLUS





RN 400767-93-3 CAPLUS
CN Cyclopentanecarboxamide, N-[(3,4-dichlorophenyl)methyl]-3-[4-(4-fluorophenyl)-1-piperidinyl]-1-(1-methylethyl)-, (1R,3S)-rel- (CA INDEX NAME)

Relative stereochemistry.



RN 400767-95-5 CAPLUS
CN Cyclopentanecarboxamide, N-[(3,4-difluorophenyl)methyl]-3-[4-(4-fluorophenyl)-1-piperidinyl]-1-(1-methylethyl)-, (1R,3S)-rel- (CA INDEX NAME)

Relative stereochemistry.



RN 400767-96-6 CAPLUS
CN Cyclopentanecarboxamide, 3-[4-(4-fluorophenyl)-1-piperidinyl]-N-[(2-methoxyphenyl)methyl]-1-(1-methylethyl)-, (1R,3S)-rel- (CA INDEX NAME)

Relative stereochemistry.



RN 400767-97-7 CAPLUS
CN Cyclopentanecarboxamide, 3-[4-(4-fluorophenyl)-1-piperidinyl]-1-(1-methylethyl)-N-(phenylmethyl)-, (1R,3S)-rel- (CA INDEX NAME)

Relative stereochemistry.



RN 400767-98-8 CAPLUS
CN Cyclopentanecarboxamide, 3-[4-(4-fluorophenyl)-1-piperidinyl]-1-(1-methylethyl)-N-(1-phenylethyl)-, (1R,3S)-rel- (CA INDEX NAME)

Relative stereochemistry.







(trifluoromethyl)phenyl]methyl]-, (1R,3S)-rel- (CA INDEX NAME)

Relative stereochemistry.



RN 400768-11-3 CAPLUS
CN Cyclopentanecarboxamide, 1-cyclopropyl-N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-3-(4-phenyl-1-piperidinyl)-, (1R,3S)-rel- (CA INDEX NAME)

Absolute stereochemistry.



RN 400768-14-1 CAPLUS
CN Cyclopentanecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-1-cyclopropyl-3-[4-(4-fluorophenyl)-1-piperidinyl]-, (1R,3S)- (CA INDEX NAME)

Absolute stereochemistry.







RN 400767-99-9 CAPLUS
CN Cyclopentanecarboxamide, 3-[4-(4-fluorophenyl)-1-piperidinyl]-1-(1-methylethyl)-N-(1-methyl-1-phenylethyl)-, (1R,3S)-rel- (CA INDEX NAME)

Relative stereochemistry.



RN 400768-00-5 CAPLUS
CN Benzeneacetic acid, α-[[[(1R,3S)-3-[4-(4-fluorophenyl)-1-piperidinyl]-1-(1-methylethyl)cyclopentyl]carbonyl]amino]-3-(trifluoromethyl)-, methyl ester, rel- (CA INDEX NAME)

Relative stereochemistry.



RN 400768-01-6 CAPLUS
CN Cyclopentanecarboxamide, 1-(1-methylethyl)-3-(4-phenyl-1-piperidinyl)-N-[[3-(trifluoromethyl)phenyl]methyl]-, (1S,3R)- (CA INDEX NAME)

Absolute stereochemistry.







RN 400768-15-2 CAPLUS
CN Cyclopentanecarboxamide, 1-cyclopropyl-3-[4-(4-fluorophenyl)-1-piperidinyl]-N-[[3-fluoro-5-(trifluoromethyl)phenyl]methyl]-, (1S,3R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 400768-16-3 CAPLUS
CN Cyclopentanecarboxamide, 1-cyclopropyl-3-[4-(4-fluorophenyl)-1-piperidinyl]-N-[[3-fluoro-5-(trifluoromethyl)phenyl]methyl]-, (1R,3S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 400769-17-4 CAPLUS
CN Cyclopentanecarboxamide, 1-cyclopropyl-3-[4-(4-fluorophenyl)-1-piperidinyl]-N-[[3-(trifluoromethyl)phenyl]methyl]-, (1S,3R)- (CA INDEX NAME)

Absolute stereochemistry.





RN 400768-02-7 CAPLUS
CN Cyclopentanecarboxamide, 1-(1-methylethyl)-3-(4-phenyl-1-piperidinyl)-N-[[3-(trifluoromethyl)phenyl]methyl]-, (1R,3S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 400768-10-7 CAPLUS
CN Cyclopentanecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-1-cyclopropyl-3-(4-phenyl-1-piperidinyl)-, (1R,3S)-rel- (CA INDEX NAME)

Relative stereochemistry.



RN 400768-11-8 CAPLUS
CN Cyclopentanecarboxamide, 1-cyclopropyl-N-[[3-fluoro-5-(trifluoromethyl)phenyl]methyl]-3-(4-phenyl-1-piperidinyl)-, (1R,3S)-rel- (CA INDEX NAME)

Relative stereochemistry.



RN 400768-12-9 CAPLUS
CN Cyclopentanecarboxamide, 1-cyclopropyl-3-(4-phenyl-1-piperidinyl)-N-[[3-







RN 400768-15-5 CAPLUS
CN Cyclopentanecarboxamide, 1-cyclopropyl-3-[4-(4-fluorophenyl)-1-piperidinyl]-N-[[3-(trifluoromethyl)phenyl]methyl]-, (1R,3S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 400768-33-4 CAPLUS
CN Cyclopentanecarboxamide, 3-[4-(4-fluorophenyl)-1-piperidinyl]-N-[[3-fluoro-5-(trifluoromethyl)phenyl]methyl]-1-(1-hydroxy-1-methylethyl)-, (1R,3R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 400769-34-5 CAPLUS

CN Cyclopentanecarboxamide, 3-[4-(4-fluorophenyl)-1-piperidinyl]-N-[[3-fluoro-5-(trifluoromethyl)phenyl]methyl]-1-(2-methyl-2-propenyl)-, (1S,3R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 400768-53-8 CAPLUS
CN Cyclopentanecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-3-(4-phenyl-1-piperidinyl)-, (1S,3R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 400768-54-9 CAPLUS
CN Cyclopentanecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-3-(4-phenyl-1-piperidinyl)-, (1R,3S)- (CA INDEX NAME)

Absolute stereochemistry.







INDEX NAME)

Relative stereochemistry.



RN 400766-68-5 CAPLUS
CN Cyclopentanecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-3-[4-(4-fluorophenyl)-1-piperidinyl]-1-(2-methylpropyl)-, (1R,3S)-rel- (CA INDEX NAME)

Relative stereochemistry.



RN 400769-63-6 CAPLUS
CN Cyclopentanecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-1-(2-methylpropyl)-3-(1-piperidinyl)-, (1R,3R)-rel- (CA INDEX NAME)

Relative stereochemistry.







RN 400768-55-0 CAPLUS
CN Cyclopentanecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-3-(4-phenyl-1-piperidinyl)-, (1R,3R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 400768-56-1 CAPLUS
CN Cyclopentanecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-3-(4-phenyl-1-piperidinyl)-, (1S,3S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 400768-63-0 CAPLUS
CN Cyclopentanecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-1-(2-methylpropyl)-3-(4-phenyl-1-piperidinyl)-, (1R,3R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 400768-64-1 CAPLUS





RN 400768-70-9 CAPLUS
CN Cyclopentanecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-1-(2-methylpropyl)-3-(1-piperidinyl)-, (1R,3S)-rel- (CA INDEX NAME)

Relative stereochemistry.



RN 400768-71-0 CAPLUS
CN Cyclopentanecarboxamide, N-[[3-fluoro-5-(trifluoromethyl)phenyl]methyl]-1-(2-methylpropyl)-3-(4-phenyl-1-piperidinyl)-, (1R,3R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 400768-72-1 CAPLUS
CN Cyclopentanecarboxamide, N-[[3-fluoro-5-(trifluoromethyl)phenyl]methyl]-1-(2-methylpropyl)-3-(4-phenyl-1-piperidinyl)-, (1S,3S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 400768-73-2 CAPLUS





CN Cyclopentanecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-1-(2-methylpropyl)-3-(4-phenyl-1-piperidinyl)-, (1S,3S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 400768-65-2 CAPLUS
CN Cyclopentanecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-1-(2-methylpropyl)-3-(4-phenyl-1-piperidinyl)-, (1S,3R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 400768-66-3 CAPLUS
CN Cyclopentanecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-1-(2-methylpropyl)-3-(4-phenyl-1-piperidinyl)-, (1R,3S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 400768-67-4 CAPLUS
CN Cyclopentanecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-3-[4-(4-fluorophenyl)-1-piperidinyl]-1-(2-methylpropyl)-, (1R,3R)-rel- (CA





CN Cyclopentanecarboxamide, N-[[3-fluoro-5-(trifluoromethyl)phenyl]methyl]-1-(2-methylpropyl)-3-(4-phenyl-1-piperidinyl)-, (1S,3R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 400768-74-3 CAPLUS
CN Cyclopentanecarboxamide, N-[[3-fluoro-5-(trifluoromethyl)phenyl]methyl]-1-(2-methylpropyl)-3-(4-phenyl-1-piperidinyl)-, (1R,3S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 400768-75-4 CAPLUS
CN Cyclopentanecarboxamide, 3-[4-(4-fluorophenyl)-1-piperidinyl]-N-[[3-fluoro-5-(trifluoromethyl)phenyl]methyl]-1-(2-methylpropyl)-, (1R,3R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 400768-76-5 CAPLUS
CN Cyclopentanecarboxamide, 3-[4-(4-fluorophenyl)-1-piperidinyl]-N-[[3-fluoro-5-(trifluoromethyl)phenyl]methyl]-1-(2-methylpropyl)-, (1S,3S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 400768-78-7 CAPLUS
CN Cyclopentanecarboxamide, 3-[4-(4-fluorophenyl)-1-piperidinyl]-N-[[3-fluoro-5-(trifluoromethyl)phenyl]methyl]-1-(2-methylpropyl)-, (1R,3S)-rel- (CA INDEX NAME)

Relative stereochemistry.



RN 400768-83-4 CAPLUS
CN Cyclopentanecarboxamide, N-[[3-fluoro-5-(trifluoromethyl)phenyl]methyl]-1-(2-methylpropyl)-3-(1-piperidinyl)-, (1R,3R)-rel- (CA INDEX NAME)

Relative stereochemistry.







RN 400768-90-3 CAPLUS
CN Cyclopentanecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-3-[4-(4-fluorophenyl)-1-piperidinyl]-1-(1-methylethyl)-, (1R,3S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 400768-96-9 CAPLUS
CN Cyclopentanecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-1-(1-methylethyl)-3-(1-piperidinyl)-, (1R,3S)-rel- (CA INDEX NAME)

Relative stereochemistry.



RN 400768-97-0 CAPLUS







RN 400768-84-5 CAPLUS
CN Cyclopentanecarboxamide, N-[[3-fluoro-5-(trifluoromethyl)phenyl]methyl]-1-(2-methylpropyl)-3-(1-piperidinyl)-, (1R,3S)-rel- (CA INDEX NAME)

Relative stereochemistry.



RN 400768-85-6 CAPLUS
CN Cyclopentanecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-1-(1-methylethyl)-3-(4-phenyl-1-piperidinyl)-, (1S,3R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 400768-86-7 CAPLUS
CN Cyclopentanecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-1-(1-methylethyl)-3-(4-phenyl-1-piperidinyl)-, (1R,3S)- (CA INDEX NAME)

Absolute stereochemistry.





CN Cyclopentanecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-1-(1-methylethyl)-3-(1-piperidinyl)-, (1R,3R)-rel- (CA INDEX NAME)

Relative stereochemistry.



RN 400769-02-0 CAPLUS
CN Cyclopentanecarboxamide, N-[[3-fluoro-5-(trifluoromethyl)phenyl]methyl]-1-(1-methylethyl)-3-(1-piperidinyl)-, (1S,3R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 400769-03-1 CAPLUS
CN Cyclopentanecarboxamide, N-[[3-fluoro-5-(trifluoromethyl)phenyl]methyl]-1-(1-methylethyl)-3-(1-piperidinyl)-, (1R,3S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 400769-04-2 CAPLUS
CN Cyclopentanecarboxamide, N-[[3-fluoro-5-(trifluoromethyl)phenyl]methyl]-1-(1-methylethyl)-3-(1-piperidinyl)-, (1R,3R)-rel- (CA INDEX NAME)







RN 400768-87-8 CAPLUS
CN Cyclopentanecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-1-(1-methylethyl)-3-(4-phenyl-1-piperidinyl)-, (1R,3R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 400768-88-9 CAPLUS
CN Cyclopentanecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-1-(1-methylethyl)-3-(4-phenyl-1-piperidinyl)-, (1S,3S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 400768-89-0 CAPLUS
CN Cyclopentanecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-3-[4-(4-fluorophenyl)-1-piperidinyl]-1-(1-methylethyl)-, (1S,3R)- (CA INDEX NAME)

Absolute stereochemistry.





Relative stereochemistry.



RN 400769-05-3 CAPLUS
CN Cyclopentanecarboxamide, 3-[4-(4-fluorophenyl)-1-piperidinyl]-N-[[3-fluoro-5-(trifluoromethyl)phenyl]methyl]-1-(1-methylethyl)-, (1R,3S)-rel- (CA INDEX NAME)

Relative stereochemistry.



RN 400769-06-4 CAPLUS
CN Cyclopentanecarboxamide, 3-[4-(4-fluorophenyl)-1-piperidinyl]-N-[[3-fluoro-5-(trifluoromethyl)phenyl]methyl]-1-(1-methylethyl)-, (1R,3R)-rel- (CA INDEX NAME)

Relative stereochemistry.



RN 400769-07-5 CAPLUS
CN Cyclopentanecarboxamide, 1-(1-methylethyl)-3-(1-piperidinyl)-N-[[3-(trifluoromethyl)phenyl]methyl]-, (1R,3S)-rel- (CA INDEX NAME)

Relative stereochemistry.



RN 400769-08-6 CAPLUS
CN Cyclopentanecarboxamide, 1-(1-methylethyl)-3-(1-piperidinyl)-N-[[3-(trifluoromethyl)phenyl]methyl]-, (1R,3R)-rel- (CA INDEX NAME)

Relative stereochemistry.



RN 400769-15-5 CAPLUS
CN Cyclopentanecarboxamide, 3-[4-(4-fluorophenyl)-1-piperidinyl]-1-(1-methylethyl)-N-[[3-(trifluoromethyl)phenyl]methyl]-, (1R,3S)-rel- (CA INDEX NAME)

Relative stereochemistry.



RN 400769-16-6 CAPLUS
CN Cyclopentanecarboxamide, 3-[4-(4-fluorophenyl)-1-piperidinyl]-1-(1-methylethyl)-N-[[3-(trifluoromethyl)phenyl]methyl]-, (1R,3R)-rel- (CA INDEX NAME)





RN 400769-30-4 CAPLUS
CN Cyclopentanecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-3-[4-(4-fluorophenyl)-1-piperidinyl]-1-[2-(1H-tetrazol-5-yl)cyclopropyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 403769-31-5 CAPLUS
CN Cyclopentanecarboxamide, 3-[4-(4-fluorophenyl)-1-piperidinyl]-N-[[3-fluoro-5-(trifluoromethyl)phenyl]methyl]-1-[2-(5-methyl-1,3,4-oxadiazol-2-yl)cyclopropyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 400769-32-6 CAPLUS
CN Cyclopentanecarboxamide, 3-[4-(4-fluorophenyl)-1-piperidinyl]-N-[[3-fluoro-





Relative stereochemistry.



RN 400769-23-5 CAPLUS
CN Cyclopentanecarboxamide, 3-(4-fluoro-4-phenyl-1-piperidinyl)-N-[[3-fluoro-5-(trifluoromethyl)phenyl]methyl]-1-(1-methylethyl)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 400769-24-6 CAPLUS
CN Cyclopentanecarboxamide, 1-[2-[(ethylamino)carbonyl]cyclopropyl]-3-[4-(4-fluorophenyl)-1-piperidinyl]-N-[[3-fluoro-5-(trifluoromethyl)phenyl]methyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 400769-27-9 CAPLUS
CN Cyclopentanecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-1-





[(1R,2R)-2-cyanocyclopropyl]-3-[4-(4-fluorophenyl)-1-piperidinyl]-, (1S,3S)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 400769-28-0 CAPLUS
CN Cyclopentanecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-1-[(1R,2S)-2-cyanocyclopropyl]-3-[4-(4-fluorophenyl)-1-piperidinyl]-, (1S,3R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 400769-29-1 CAPLUS
CN Cyclopentanecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-1-[(1R,2S)-2-cyanocyclopropyl]-3-[4-(4-fluorophenyl)-1-piperidinyl]-, (1S,3S)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.









● HCl

RN 400769-35-9 CAPLUS
CN Cyclopentanecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-3-[4-(4-fluorophenyl)-1-piperidinyl]-1-(hydroxymethyl)-, (1R,3S)-rel- (CA INDEX NAME)

Relative stereochemistry.



RN 400769-36-0 CAPLUS
CN Cyclopentanecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-3-[4-(4-fluorophenyl)-1-piperidinyl]-1-formyl-, (1R,3S)-rel- (CA INDEX NAME)

Relative stereochemistry.



RN 400769-37-1 CAPLUS
CN Cyclopentanecarboxamide, 1-[(acetyloxy)methyl]-N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-3-[4-(4-fluorophenyl)-1-piperidinyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 400769-38-2 CAPLUS
CN Cyclopentanecarboxamide, 1-[2-(acetyloxy)ethyl]-N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-3-[4-(4-fluorophenyl)-1-piperidinyl]-, (1R,3S)-rel- (CA INDEX NAME)

Relative stereochemistry.







PAGE 1-A



PAGE 2-A

● HCl

RN 400769-44-0 CAPLUS
CN 1,1-Cyclopentanedicarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-3-[4-(4-fluorophenyl)-1-piperidinyl]-N'-(1-methylethyl)-, (1R,3R)-rel- (CA INDEX NAME)

Relative stereochemistry.



RN 400769-45-1 CAPLUS
CN 1,1-Cyclopentanedicarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-3-[4-(4-fluorophenyl)-1-piperidinyl]-N'-methyl-, (1R,3S)-rel- (CA INDEX NAME)

Relative stereochemistry.





RN 400769-39-3 CAPLUS
CN Cyclopentanecarboxamide, 1-(aminomethyl)-N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-3-[4-(4-fluorophenyl)-1-piperidinyl]-, (1R,3S)-rel- (CA INDEX NAME)

Relative stereochemistry.



RN 400769-40-6 CAPLUS
CN Cyclopentanecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-3-[4-(4-fluorophenyl)-1-piperidinyl]-1-[[(methylsulfonyl)amino]methyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 400769-41-7 CAPLUS
CN Carbamic acid, [[(1R,3S)-1-[[[[3,5-bis(trifluoromethyl)phenyl]methyl]amino]carbonyl]-3-[4-(4-fluorophenyl)-1-piperidinyl]cyclopentyl]methyl]-, methyl ester, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.







RN 400769-46-2 CAPLUS
CN Cyclopentanecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-3-[4-(4-fluorophenyl)-1-piperidinyl]-1-(1-pyrrolidinylcarbonyl)-, (1R,3R)-rel- (CA INDEX NAME)

Relative stereochemistry.



L8 ANSWER 17 OF 23 CAPLUS COPYRIGHT 2006 ACS on STN
2001:923765 Document No. 136:37947 Preparation of amino acid derivatives as serine protease inhibitors. Liebeschuetz, John Walter; Murray, Christopher William; Young, Stephen Clinton; Camp, Nicholas Paul; Jones, Stuart Donald; Wylie, William Alexander; Masters, John Joseph; Wiley, Michael Robert; Sheehan, Scott Martin; Engel, David Birenbaum; Watson, Brian Morgan (Eli Lilly and Company, USA). PCT Int. Appl. WO 2001096303 A1 20011220, 188 pp. DESIGNATED STATES: W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM; RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, CY, DE, DK, ES, FI, FR, GA, GB, GR, IE, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN, TD, TG, TR. (English). CODEN: PIXXD2. APPLICATION: WO 2001-GB2551 20010612. PRIORITY: WO 2000-GB2302 20000613; GB 2000-30305 20001213.







RN 400769-42-8 CAPLUS
CN Cyclopentanecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-1-[(dimethylamino)methyl]-3-[4-(4-fluorophenyl)-1-piperidinyl]-, (1R,3S)-rel- (CA INDEX NAME)

Relative stereochemistry.



RN 400769-43-9 CAPLUS
CN Cyclopentanecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-3-[4-(4-fluorophenyl)-1-piperidinyl]-1-(4H-1,2,4-triazol-4-ylmethyl)-, monohydrochloride, (1R,3S)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.





AB Compds. R2-X-X-Y(Cy)-L-Lp(D)n {R2 is a 5- or 6-membered aromatic carbon ring optionally interrupted by a N, O or S ring atom, optionally substituted at the 3 and/or 4 position or forms a fused ring system at these positions, which is an optionally substituted 5- or 6-membered carbocyclic or heterocyclic ring, or substituted at the position alpha to X-X; X is a C, N, O or S atom or a CO, CR1a, C(R1a)2 or NR1a group, where R1a represents H, OH, alkoxy, alkyl, aminoalkyl, hydroxyalkyl, alkoxyalkyl, alkoxycarbonyl, alkylaminocarbonyl, alkoxycarbonylamino, acyloxymethoxycarbonyl or alkylamino optionally substituted by OH, alkylamino, alkoxy, oxo, aryl or cycloalkyl; Y is a N atom or a CR1b group (R1b defined as for R1a); Cy is an (un)substituted, (un)saturated, mono- or polycyclic, homo- or heterocyclic group; L is an organic linker group containing 1 to 5 backbone atoms selected from C, N, O and S, or a branched alkyl or cyclic group; -Lp(D)n is 1-[R1C-(Lb)u-(G)t-(La)s]-3-pyrrolidinyl or -4-piperidinyl, where s, t and u = 0 or 1; La and Lb is a single bond, CO, O, NH or alkylimino; G = alkanediyl; R1C = alkyl, cycloalkyl, indanyl, pyridyl, tetrahydropyranyl, (un)substituted Ph, etc.] or their physiol.-tolerable salts were prepared for use as serine protease and factor Xa inhibitors in the treatment of cardiovascular disorders. Compds. of the invention were found to significantly elongate the partial thromboplastin time (prothrombin time). Thus, 4-[(4-methoxybenzoyl-D-phenylglycinyl)aminomethyl]-1-isopropylpiperidine was prepared in the first of 106 examples.

IT 313488-58-3P 313488-66-3P 313488-70-9P
313488-73-2P 313488-06-4P 313488-07-5P
313489-13-3P 380899-68-3P 380899-70-7P
380899-95-6P 380900-25-4P 380900-27-6P
380900-79-8P 380900-83-4P 380900-86-9P
380900-90-3P 380900-92-5P 380900-94-7P
380900-96-9P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of amino acid derivs. as serine protease inhibitors)

RN 313488-58-3 CAPLUS
CN Benzeneacetamide, N-[(1-cyclopentyl-4-piperidinyl)methyl]-α-[(4-methoxybenzoyl)amino]-, (αR)- (CA INDEX NAME)

Absolute stereochemistry.



RN 313488-66-3 CAPLUS
CN 1H-Indole-6-carboxamide, N-[(1R)-2-[[(1-cyclopentyl-4-piperidinyl)methyl]amino]-2-oxo-1-phenylethyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 313488-70-9 CAPLUS
CN Benzeneacetamide, N-(1-cyclopentyl-4-piperidinyl)-α-[(4-methoxybenzoyl)amino]-, (αR)- (CA INDEX NAME)

Absolute stereochemistry.



RN 312488-73-2 CAPLUS
CN 1H-Indole-6-carboxamide, N-[(1R)-2-[(1-cyclopentyl-4-piperidinyl)amino]-2-oxo-1-phenylethyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 313489-06-4 CAPLUS
CN 1H-Indole-2-carboxamide, 5-chloro-N-[(1R)-2-[[(1-cyclopentyl-4-piperidinyl)methyl]amino]-2-oxo-1-phenylethyl]- (CA INDEX NAME)

Absolute stereochemistry.







RN 313489-07-5 CAPLUS
CN 1H-Indole-6-carboxamide, N-[(1R)-2-[[(1-cyclopentyl-4-piperidinyl)methyl]amino]-2-oxo-1-phenylethyl]-3-methyl- (CA INDEX NAME)

Absolute stereochemistry.



RN 313489-13-3 CAPLUS
CN 4-Piperidinecarboxamide, 1-cyclopentyl-N-[(2R)-2-[(4-methoxybenzoyl)amino]-2-phenylethyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 380899-68-3 CAPLUS
CN 1H-Indole-6-carboxamide, 3-chloro-N-[(1R)-2-[[(1-cyclopentyl-4-piperidinyl)methyl]amino]-2-oxo-1-phenylethyl]- (CA INDEX NAME)

Absolute stereochemistry.







RN 380899-70-7 CAPLUS
CN Benzo[b]thiophene-2-carboxamide, 6-chloro-N-[(1R)-2-[[(1-cyclopentyl-4-piperidinyl)methyl]amino]-2-oxo-1-phenylethyl]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 380899-69-4
CMF C28 H32 Cl N3 O2 S

Absolute stereochemistry.



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 380899-95-6 CAPLUS
CN 1H-Indole-6-carboxamide, N-[(1R)-2-[[(1-cyclopentyl-4-piperidinyl)methyl]methylamino]-2-oxo-1-phenylethyl]-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.







● HCl

RN 380900-25-4 CAPLUS
CN 1H-Indole-6-carboxamide, 3-chloro-N-[2-[[(1-cyclopentyl-4-piperidinyl)methyl]amino]-1-(2-naphthalenyl)-2-oxoethyl]- (CA INDEX NAME)



RN 380900-27-6 CAPLUS
CN 1H-Indole-6-carboxamide, 3-chloro-N-[2-[[(1-cyclopentyl-4-piperidinyl)methyl]amino]-1-(1-naphthalenyl)-2-oxoethyl]- (CA INDEX NAME)







RN 380900-79-6 CAPLUS
CN Benzeneacetamide, 2-chloro-N-[(1-cyclopentyl-4-piperidinyl)methyl]-α-[(4-methoxybenzoyl)amino]- (CA INDEX NAME)



RN 380900-83-4 CAPLUS
CN 1H-Indole-2-carboxamide, 5-chloro-N-[1-(2-chlorophenyl)-2-[[(1-cyclopentyl-4-piperidinyl)methyl]amino]-2-oxoethyl]- (CA INDEX NAME)



RN 380900-66-9 CAPLUS
CN 1H-Indole-6-carboxamide, 3-chloro-N-[2-[[(1-cyclopentyl-4-piperidinyl)methyl]amino]-2-oxo-1-[2-(trifluoromethyl)phenyl]ethyl]-, monohydrochloride (9CI) (CA INDEX NAME)







● HCl

RN 380900-90-3 CAPLUS
CN 1H-Indole-6-carboxamide, N-[2-[[(1-cyclopentyl-4-piperidinyl)methyl]amino]-2-oxo-1-[2-(trifluoromethyl)phenyl]ethyl]-3-methyl-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 380900-92-5 CAPLUS
CN 1H-Indole-2-carboxamide, 5-chloro-N-[2-[[(1-cyclopentyl-4-piperidinyl)methyl]amino]-2-oxo-1-[2-(trifluoromethyl)phenyl]ethyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 380900-94-7 CAPLUS
CN 1H-Indole-6-carboxamide, N-[(1R)-2-[[2-(1-cyclopentyl-4-

piperidinyl]ethyl]amino]-2-oxo-1-phenylethyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 380900-96-3 CAPLUS
CN 1H-Indole-6-carboxamide, 3-chloro-N-[(1R)-2-[[2-(1-cyclopentyl-4-piperidinyl]ethyl]amino]-2-oxo-1-phenylethyl]- (CA INDEX NAME)

Absolute stereochemistry.



IT 313490-61-8P 380901-32-6P 380902-73-4P
380902-83-0P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of amino acid derivs. as serine protease inhibitors)
RN 313490-61-8 CAPLUS
CN Carbamic acid, [(1R)-2-[[(1-cyclopentyl-4-piperidinyl]methyl]amino]-2-oxo-1-phenylethyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.





binding assays and 3 in-vivo models. For instance, 4-methylbenzylamine was reductively alkylated with 1-methyl-4-piperidone (MeOH, HOAc, NaCNBH3, 20 h., room temperature). The resulting amine was alkylated with 4-methoxyphenylacetyl chloride (DCM, 4 h., room temperature) to give II, isolated as the hydrochloride salt and subsequently purified by chromatog. Many of the examples had pIC50 (-log IC50) = 7.5 - 9.0 for HT2A. I are used for the treatment of disease in which modification of serotonergic receptor activity has a beneficial effect.
IT 359878-34-5P 359878-96-9P 359879-34-0P
359881-73-5P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(drug; preparation of N-piperidinyl-N-alkyl-aryl-acetamides and N,N,N'-substituted ureas as 5-HT2A inverse agonists)
RN 359878-34-5 CAPLUS
CN Benzeneacetamide, N-[(4-chlorophenyl)methyl]-N-(1-cyclopentyl-4-piperidinyl)-4-methoxy- (CA INDEX NAME)



RN 359879-96-9 CAPLUS
CN Benzeneacetamide, N-(1-cyclopentyl-4-piperidinyl)-4-methoxy-N-[(4-methylphenyl)methyl]- (CA INDEX NAME)



RN 359879-34-0 CAPLUS
CN Benzeneacetamide, 4-chloro-N-(1-cyclopentyl-4-piperidinyl)-N-[(4-methylphenyl)methyl]- (CA INDEX NAME)







RN 380901-32-6 CAPLUS
CN Carbamic acid, [(1R)-2-[[(1-cyclopentyl-4-piperidinyl]methyl]methylamino]-2-oxo-1-phenylethyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 380902-73-4 CAPLUS
CN Carbamic acid, [2-[[(1-cyclopentyl-4-piperidinyl)methyl]amino]-2-oxo-1-[2-(trifluoromethyl)phenyl]ethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 380902-83-0 CAPLUS
CN Carbamic acid, [(1R)-2-[[2-(1-cyclopentyl-4-piperidinyl)ethyl]amino]-2-oxo-1-phenylethyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.







RN 359881-73-5 CAPLUS
CN Benzeneacetamide, 4-chloro-N-(1-cyclopentyl-4-piperidinyl)-N-[(4-methylphenyl)methyl]-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

IT 359879-35-6P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of N-piperidinyl-N-alkyl-aryl-acetamides and N,N,N'-substituted ureas as 5-HT2A inverse agonists)
RN 359879-35-6 CAPLUS
CN Benzeneacetamide, N-[(4-chlorophenyl)methyl]-N-(1-cyclopentyl-4-piperidinyl)-4-methoxy-, hydrochloride (1:1) (CA INDEX NAME)







L8 ANSWER 18 OF 23 CAPLUS COPYRIGHT 2008 ACS on STN
2001:676749 Document No. 135:242140 Preparation of N-piperidinyl-N-alkyl-acetamides and N,N,N'-substituted ureas as 5-HT2A inverse agonists/antagonists. Andersson, Carl M.; Croston, Glenn; Hansen, E. L.; Ulidam, A. K. (Acadia Pharmaceuticals, Inc., USA). PCT Int. Appl. WO 2001066521 A1 20010913, 150 pp. DESIGNATED STATES: W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM; RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, CY, DE, DK, ES, FI, FR, GA, GB, GR, IE, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN, TD, TG, TR. (English). CODEN: PIXXD2. APPLICATION: WO 2001-US7187 20010306. PRIORITY: US 2000-PV187289 20000306.
GI



AB Title compds. Ar1-Y2-Y1-N(Z)-C:W-X1-X2-Ar2 [Z = NR-substituted piperidinyl, tropanyl,azetidinyl, etc.; R = H, cyclic/straight-chain acyclic organyl group, hydroxyalkyl, aminoalkyl, araikyl or heteroaralkyl group; X1 = CH2, vinylene, NH or N-alkyl; X2 = CH2, or, when X1 = CH2 or vinylene, X2 = CH2 or a bond; or when X1 is CH2, X2 = O, S, NH, N(lower alkyl) or a bond; Y1 = CH2 and Y2 = CH2, vinylene, ethylene, propylene, bond; or Y1 = bond and Y2 = vinylene; or Y1 = ethylene and Y2 = O, S, NH, N(lower alkyl); Ar1 and Ar2 = (un)substituted (hetero)aryl provided that Ar1 and Ar2 are not simultaneously phenyl; W = O, S; I] were prepared Examples include over 130 compds. synthesized, 5 serotonin receptor







● HCl

L8 ANSWER 19 OF 23 CAPLUS COPYRIGHT 2008 ACS on STN
2001:73539 Document No. 134:131552 Preparation of heterocyclic compounds as antithrombotic agents. Blagg, Julian; Brown, Alan Daniel; Gautier, Elisabeth Colette Louise; Smith, Julian Duncan; McElroy, Andrew Brian (Pfizer Inc., USA). U.S. US 6180627 B1 20010130, 74 pp. (English). CODEN: USXXAM. APPLICATION: US 1999-372200 19990811.
GI



AB The title compds. I [R1, R3 = H, alkyl, perfluoroalkyl, etc.; R2 = H, Me, CF3; R4, R5 = H, alkyl; R6 = H, F, Cl, alkyl, etc.; R5R6 maybe linked to form C2-3 linking group; Y = H, Cl, F, Br, Me, CF3; V = C, N; W = CH, CF, CCl, N; X = N; BA = BCR8R9, BCH2CR8R9, BCR9R9CH2, etc.; R8, R9 = H, (CH2)mNR10R11, CH2O(CH2)2NR10R11; R5R9 may form N-containing 4- to 6-membered

heterocyclyl; m = 0-2; R10, R11 = H, alkyl, etc.; E = Ph, 5-6 membered heterocyclyl contalning ≤2 heteroatoms; R7 = H, alkyl, perfluoroalkyl, etc.] and their pharmacol. acceptable salts, useful for treatment or prevention of deep-vein thrombosis, disseminated intravascular coagulation, transient ischemic attack, etc, were prepared and formulated. E.g., a multi-step synthesis of the acetamide (R,S)-II was given. All exemplified compds. I showed Ki < 3x10-7 M against thrombin in vitro and Ki of > ix10-5 M against trypsin in vitro.

IT 259539-00-9P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of heterocyclic compds. as antithrombotic agents)

RN 259539-00-9 CAPLUS
CN 1(2H)-Pyrazineacetamide, 3-[[[(2R,4R)-1-cyclopentyl-4-methyl-2-piperidinyl]methyl]amino]-N-(1H-indol-5-ylmethyl)-6-methyl-2-oxo- (CA INDEX NAME)

Absolute stereochemistry.



L6 ANSWER 20 OF 23 CAPLUS COPYRIGHT 2008 ACS on STN
2000:900614 Document No. 134:56958 Preparation of amino acid derivatives as serine protease inhibitors. Liebeschuetz, John Walter; Lyons, Amanda Jane; Murray, Christopher William; Rimmer, Andrew David; Young, Stephen Clinton; Camp, Nicholas Paul; Jones, Stuart Donald; Morgan, Phillip John; Richards, Simon James; Wylie, William Alexander; Masters, John Joseph; Wiley, Michael Robert (Eli Lilly and Company, USA; Protherics Molecular Design Limited). PCT Int. Appl. WO 2000076971 A2 20001221, 261 pp. DESIGNATED STATES: W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM; RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, CY, DE, DK, ES, FI, FR, GA, GB, GR, IE, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN, TD, TG. (English). CODEN: PIXXD2. APPLICATION: WO 2000-GB2302 20000613. PRIORITY: GB 1999-13823 19990614; US 1999-PV142064 19990702; GB 1999-19741 19990809; GB 1999-29553 19991214.

AB Compds. R2-X-X-Y(Cy)-L-Lp(D)n [R2 represents a 5- or 6-membered aromatic carbon ring optionally interrupted by a N, O or S ring atom, optionally substituted at the 3 and/or 4 position or forms a fused ring system at these positions, which is an optionally substituted 5 or 6 membered carbocyclic or heterocyclic ring; X is a C, N, O or S atom or a CO, CR1a, C(R1a)2 or NR1a group, where





R1a represents H, OH, alkoxy, alkyl, aminoalkyl, hydroxyalkyl, alkoxyalkyl, alkoxycarbonyl, alkylaminocarbonyl, alkoxycarbonylamino, acyloxymethoxycarbonyl or alkylamino optionally substituted by OH, alkylamino, alkoxy, oxo, aryl or cycloalkyl; L is an organic linker group containing 1 to 5 backbone atoms selected from C, N, O and S, or a branched alkyl or cyclic group; Y is a N atom or a CR1b group (R1b defined as for R1a); Cy is an (un)substituted, (un)saturated, mono- or polycyclic, homo- or heterocyclic group; Lp is a lipophilic organic group; D is a hydrogen bond donor group; n = 0-2] were prepared for use as serine protease inhibitors. Compds. of the invention were found to significantly elongate the partial thromboplastin time (prothrombin time). Thus, 1-(3-amino-2-naphthoyl-D-phenylglycinyl)-4,4'-bispiperidine was prepared and shown to double the prothrombin time at a concentration of 26 μM.

IT 313488-58-3P 313488-66-3P 313488-70-9P
313488-73-2P 313489-06-4P 313489-07-5P
313489-13-3P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of amino acid derivs. as serine protease inhibitors)

RN 313488-58-3 CAPLUS
CN Benzeneacetamide, N-[(1-cyclopentyl-4-piperidinyl)methyl]-α-[(4-methoxybenzoyl)amino]-, (αR)- (CA INDEX NAME)

Absolute stereochemistry.



RN 313488-66-3 CAPLUS
CN 1H-Indole-6-carboxamide, N-[(1R)-2-[[(1-cyclopentyl-4-piperidinyl)methyl]amino]-2-oxo-1-phenylethyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 313488-70-9 CAPLUS
CN Benzeneacetamide, N-(1-cyclopentyl-4-piperidinyl)-α-[(4-





methoxybenzoyl)amino]-, (αR)- (CA INDEX NAME)

Absolute stereochemistry.



RN 313488-73-2 CAPLUS
CN 1H-Indole-6-carboxamide, N-[(1R)-2-[(1-cyclopentyl-4-piperidinyl)amino]-2-oxo-1-phenylethyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 313489-06-4 CAPLUS
CN 1H-Indole-2-carboxamide, 5-chloro-N-[(1R)-2-[((1-cyclopentyl-4-piperidinyl)methyl]amino]-2-oxo-1-phenylethyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 313489-07-5 CAPLUS
CN 1H-Indole-6-carboxamide, N-[(1R)-2-[[(1-cyclopentyl-4-piperidinyl)methyl]amino]-2-oxo-1-phenylethyl]-3-methyl- (CA INDEX NAME)





Absolute stereochemistry.



RN 313489-13-3 CAPLUS
CN 4-Piperidinecarboxamide, 1-cyclopentyl-N-[(2R)-2-[(4-methoxybenzoyl)amino]-2-phenylethyl]- (CA INDEX NAME)

Absolute stereochemistry.



IT 313490-61-8P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of amino acid derivs. as serine protease inhibitors)

RN 313490-61-8 CAPLUS
CN Carbamic acid, [(1R)-2-[[(1-cyclopentyl-4-piperidinyl)methyl]amino]-2-oxo-1-phenylethyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L6 ANSWER 21 OF 23 CAPLUS COPYRIGHT 2008 ACS on STN





2000:900613 Document No. 134:56957 Preparation of amino acid derivatives as serine protease inhibitors. Liebeschuetz, John Walter; Lyons, Amanda Jane; Murray, Christopher William; Rimmer, Andrew David; Young, Stephen Clinton; Camp, Nicholas Paul; Jones, Stuart Donald; Morgan, Phillip John; Richards, Simon James; Wylie, William Alexander; Lively, Sarah Elizabeth; Harrison, Martin James; Waszkowycz, Bohdan; Masters, John Joseph; Wiley, Michael John (Eli Lilly and Company, USA; Protherics Molecular Design Limited). PCT Int. Appl. WO 2000076970 A2 20001221, 350 pp. DESIGNATED STATES: W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM; RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, CY, DE, DK, ES, FI, FR, GA, GB, GR, IE, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN, TD, TG. (English). CODEN: PIXXD2. APPLICATION: WO 2000-GB2296 20000613. PRIORITY: GB 1999-13823 19990614; US 1999-PV142064 19990702; GB 1999-19741 19990809; GB 1999-29552 19991214; GB 1999-29553 19991214.

AB Compds. R2-X-X-Y(Cy)-L-Lp(D)n [R2 represents a 5- or 6-membered aromatic carbon ring optionally interrupted by a N, O or S ring atom, optionally substituted at the 3 and/or 4 position or forms a fused ring system at these positions, which is an optionally substituted 5 or 6 membered carbocyclic or heterocyclic ring; X is a C, N, O or S atom or a CO, CR1a, C(R1a)2 or NR1a group, where R1a represents H, OH, alkoxy, alkyl, aminoalkyl, hydroxyalkyl, alkoxyalkyl, alkoxycarbonyl, alkylaminocarbonyl, alkoxycarbonylamino, acyloxymethoxycarbonyl or alkylamino optionally substituted by OH, alkylamino, alkoxy, oxo, aryl or cycloalkyl; L is an organic linker group containing 1 to 5 backbone atoms selected from C, N, O and S, or a branched alkyl or cyclic group; Y is a N atom or a CR1b group (R1b defined as for R1a); Cy is an (un)substituted, (un)saturated, mono- or polycyclic, homo- or heterocyclic group; Lp is a lipophilic organic group; D is a hydrogen bond donor group; n = 0-2] were prepared for use as serine protease inhibitors. Compds. of the invention were found to significantly elongate the partial thromboplastin time (prothrombin time). Thus, 1-(3-amino-2-naphthoyl-D-phenylglycinyl)-4,4'-bispiperidine was prepared and shown to double the prothrombin time at a concentration of 26 μM.

IT 313488-58-3P 313488-66-3P 313488-70-9P
313488-73-2P 313489-06-4P 313489-07-5P
313489-13-3P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of amino acid derivs. as serine protease inhibitors)

RN 313488-58-3 CAPLUS
CN Benzeneacetamide, N-[(1-cyclopentyl-4-piperidinyl)methyl]-α-[(4-methoxybenzoyl)amino]-, (αR)- (CA INDEX NAME)

Absolute stereochemistry.







RN 313488-66-3 CAPLUS
CN 1H-Indole-6-carboxamide, N-[(1R)-2-[[(1-cyclopentyl-4-piperidinyl)methyl]amino]-2-oxo-1-phenylethyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 313488-70-9 CAPLUS
CN Benzeneacetamide, N-(1-cyclopentyl-4-piperidinyl)-α-[(4-methoxybenzoyl)amino]-, (αR)- (CA INDEX NAME)

Absolute stereochemistry.



RN 313488-73-2 CAPLUS
CN 1H-Indole-6-carboxamide, N-[(1R)-2-[(1-cyclopentyl-4-piperidinyl)amino]-2-oxo-1-phenylethyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 313489-06-4 CAPLUS

CN 1H-Indole-2-carboxamide, 5-chloro-N-[(1R)-2-[[(1-cyclopentyl-4-piperidinyl)methyl]amino]-2-oxo-1-phenylethyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 313489-07-5 CAPLUS
CN 1H-Indole-6-carboxamide, N-[(1R)-2-[[(1-cyclopentyl-4-piperidinyl)methyl]amino]-2-oxo-1-phenylethyl]-3-methyl- (CA INDEX NAME)

Absolute stereochemistry.



RN 313439-13-3 CAPLUS
CN 4-Piperidinecarboxamide, 1-cyclopentyl-N-[(2R)-2-[[4-methoxybenzoyl]amino]-2-phenylethyl]- (CA INDEX NAME)

Absolute stereochemistry.



IT 313490-61-8P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)





(preparation of amino acid derivs. as serine protease inhibitors)
RN 313490-61-8 CAPLUS
CN Carbamic acid, [(1R)-2-[[(1-cyclopentyl-4-piperidinyl)methyl]amino]-2-oxo-1-phenylethyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L8 ANSWER 22 OF 23 CAPLUS COPYRIGHT 2008 ACS on STN
2000:137279 Document No. 132:180485 Preparation of heterocyclic compounds and their use as antithrombotic agents. Black, Julian; Brown, Alan Daniel; Gaultier, Erizabet Collet Luise; Smith, Julian Duncan; McKelloy, Andrew Bralan (Pfizer Inc., USA). Jpn. Kokai Tokkyo Koho JP 2000063380 A 20000229, 95 pp. (Japanese). CODEN: JKXXAF. APPLICATION: JP 1999-229491 19990813. PRIORITY: GB 1998-17819 19980814; GB 1999-801 19990114.

GI



AB Heterocyclic compds. I [R1, R3 = H, Cl-4 (perfluoro)alkyl, Cl-4 alkoxy, F, Cl; R2 = H, Me, CF3; R4, R5 = H, Cl-4 alkyl; R6 = H, F, Cl, Cl-6 alkyl, etc.; R5R6 maybe linked to form C2-3 linking group; Y = H, Cl, F, Br, Me, CF3; V = C, N; W, X = CH, CF, CCl, N; A = (CH2)pCR8R9(CH2)q; R8, R9 = H, N-containing heterocyclyl, etc.; R8R9 may form N-containing 4- to 6-membered heterocyclyl; p, q = 0-2; B = Ph, 5- to 6-membered heterocyclyl containing ≤2 heteroatoms; R7 = H, Cl-6 (perfluoro)alkyl, Cl-6 (perfluoro)alkoxy, F, Cl, etc.] and their pharmacol. acceptable salts are useful for treatment or prevention of deep-vein thrombosis, disseminated intravascular coagulation, transient ischemic attack, etc. Catalytic hydrogenation of I [R1-R5, Y = H, R6 = Me, V = C, W, X = CH, R7BA = PhCH2CH(CH2NHZ), Z = PhCH2O2C] over Pd/C gave I [R1-R5, Y = H, R6 = Me, V = C, W, X = CH, R7BA = PhCH2CH(CH2NH2)], which inhibited thrombin with Ki of < 3 × 10-7 in vitro.
IT 259539-00-9P





RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of heterocyclic compds. as antithrombotic agents)
RN 259539-00-9 CAPLUS
CN 1(2H)-Pyrazineacetamide, 3-[[[(2R,4R)-1-cyclopentyl-4-methyl-2-piperidinyl]methyl]amino]-N-(1H-indol-5-ylmethyl)-6-methyl-2-oxo- (CA INDEX NAME)

Absolute stereochemistry.



L8 ANSWER 23 OF 23 CAPLUS COPYRIGHT 2008 ACS on STN
1986:442536 Document No. 105:42536 Original Reference No. 105:7037a,7040a Aminocyclopentyl ethers. Preparation and pharmaceutical formulation. Wallis, Christopher John; Finch, Harry; Hallett, Peter (Glaxo Group Ltd., UK). Ger. Offen. DE 3517901 A1 19851212, 43 pp. (German). CODEN: GWXXBX. APPLICATION: DE 1985-3517901 19850517. PRIORITY: GB 1984-12774 19840510; GB 1984-23083 19840912.

GI



AB Cyclopentyl ethers I [R1 = H, Me; X = cis- or trans-CH:CH, CH2CH2, m = 2-4, n = 1; X = trans-CH:CH, m = 0, n = 3; Y = 5-8-membered saturated heterocyclic amino with O, S, SO2, or NR3 (R3 = H, alkyl, aralkyl) ring members and is optionally allyl-substituted; R2 = alkyl substituted with (un)substituted Ph, thienyl, or naphthyl or R2 = cinnamyl] and their physiol. tolerable salts, useful as inhibitors of blood platelet aggregation, broncho- and vasoconstriction, and useful as antithrombotic and antiasthmatic agents (no data), were prepared by known methods. Among





the compds. prepared was II.
IT 102994-68-3P 103065-99-2P 103066-00-8P
103066-01-9P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of, as prostaglandin analog intermediate)
RN 102994-68-3 CAPLUS
CN Carbamic acid, [1-(1-naphthalenyl)ethyl]-, 2-([1,1'-biphenyl]-4-ylmethoxy)-5-(1-piperidinyl)cyclopentyl ester, [1R-[1α(R*),2α,5β]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 103065-99-2 CAPLUS
CN Carbamic acid, [1-(1-naphthalenyl)ethyl]-, 2-([1,1'-biphenyl]-4-ylmethoxy)-5-(1-piperidinyl)cyclopentyl ester, [1S-[1α(S*),2α,5β]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.







RN 103066-00-8 CAPLUS
CN Carbamic acid, [1-(1-naphthalenyl)ethyl]-, 2-([1,1'-biphenyl]-4-ylmethoxy)-5-(1-piperidinyl)cyclopentyl ester, [1R-[1α(R*),2β,5β]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 103066-01-9 CAPLUS
CN Carbamic acid, [1-(1-naphthalenyl)ethyl]-, 2-([1,1'-biphenyl]-4-ylmethoxy)-5-(1-piperidinyl)cyclopentyl ester, [1S-[1α(S*),2β,5β]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.